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Most newly synthesized messenger RNAs possess a 5’ cap and a 3’ poly(A) tail. The process of
poly(A) tail shortening, also termed deadenylation, is important for post-transcriptional gene regulation,
because deadenylation not only leads to mRNA translational inhibition but also is the first step of major
mRNA degradation. Translationally inhibited mRNAs can be stored and/or degraded in dynamic
cytoplasmic foci termed mRNA processing bodies, or P bodies, which are conserved in eukaryotes.
To shed new light on the mechanisms of P body formation and P body functions, I focused on the
link between deadenylation factors and P bodies. I found that the two major deadenylation complexes,
Pan3-Pan2 and Ccr4-Caf1, can both be enriched in P bodies. The deadenylase activity of the Ccr4-Caf1
complex is prerequisite for P body formation. Pan3, but not the deadenylase Pan2, is essential for P
body formation. While the C-terminal domain of Pan3 is important for interaction with Pan2, Pan3 Nterminal domain is important for Pan3 to form cytoplasmic foci colocalizing with P bodies and to
promote mRNA decay. Interestingly, Pan3 N-terminal domain may be phosphorylated to regulate Pan3
localization and functions. Aside from the functions of the two deadenylation complexes in P bodies, I
also studied all reported human P body proteins as a whole using bioinformatics. This effort not only
has generated a comprehensive picture of the functions of and interactions among human P body
proteins, but also has predicted proteins that may regulate P body formation and/or functions.
In summary, my study has established a direct link between mRNA deadenylation and P body
formation and has also led to new hypotheses to guide future research on how P body dynamics are
controlled.
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1.1 The Importance of Eukaryotic mRNA Poly(A) Tail

In eukaryotic cells, newly synthesized nuclear messenger RNAs generally possess a 5’ 7methylguanosine cap (m7G cap) and a 3’ polymer of adenosine-5’-monophosphate (poly(A) tail). The
poly(A) tail was added to the pre-mRNA by a large cleavage/polyadenylation machinery via a two-step
reaction. In metazoan cells, the first step is cleavage of the pre-mRNA between an A(A/U)UAAA
hexamer and a U/GU-rich region. After cleavage, the poly(A) polymerase sequentially adds 100-250
adenosine residues to the 3’ end of the cleavage product (1). The poly(A) tail is essential for both
translation initiation and mRNA stability after the nascent transcripts are exported to the cytoplasm.
1.1.1 Poly(A) tail in mRNA translation initiation

Translation of most eukaryotic mRNAs is initiated in a cap-dependent manner, which requires
several eukaryotic initiation factors (eIFs). The cap binding protein eIF4E interacts with eIF4G, which
recruits the 43S pre-initiation complex (2), consisting of the ternary complex eIF2-Met-tRNA-GTP, the
40S ribosome subunit, and several initiation factors including eIF3 (3). The recruited 43S pre-initiation
complex scans the 5’ untranslated region (UTR) of the mRNA in a 5’ to 3’ direction, until the start
codon is recognized by the Met-tRNA, which eventually leads to the joining of the 60S ribosome
subunit and formation of the 80S initiation complex ready for translation elongation (4).
By simultaneously interacting with the poly(A) binding protein (PABP) and the cap binding protein
eIF4E, the scaffold protein eIF4G physically links the 3’ poly(A) tail and the 5’ cap (5) (Fig. 1.1). The
circularization of mRNA through the cooperative interactions between PABP, eIF4G, and eIF4E
enhances the RNA helicase activity of translation initiation factors eIF4A, eIF4B, and eIF-iso4F (6),
resulting in increased translation initiation. Moreover, the circularization of mRNA may enhance the
recycling of ribosomes from the 3’ end to the 5’ end of the same mRNA, a notion further supported by
the observation of interaction between the eukaryotic release factor 3 (eRF3) and PABP (7). The
importance of poly(A) tail in cap-dependent translation initiation is exemplified during oocyte
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maturation and early embryogenesis, during which the short poly(A) tails of a set of cytoplasmic
mRNAs are elongated by cytoplasmic poly(A) polymerase. The polyadenylation transforms the mRNAs
from translationally silent to active (8). A microarray analysis following separation of cellular mRNAs
according to their poly(A) tail length indicated that yeast mRNA poly(A) tail length positively correlates
with ribosome density (ribosomes per unit length of mRNA), further confirming the importance of
poly(A) tail in translation (9).

Figure 1.1: The closed-loop model. eIF4G interacts with both the cap binding protein eIF4E and the
poly(A) tail binding protein PABP to circularize the mRNA and promote translation initiation.

Translation of some viral and about 10-15% of eukaryotic mRNAs can also be initiated in a capindependent manner (10, 11) through direct recruitment of the 40S ribosome subunit by internal
ribosome entry sites (IRES), which are highly structured regions within the 5’ UTR. IRES-mediated
translation initiation is generally not affected by conditions that inhibit cap-dependent translation
initiation, thus allowing the cells to cope with some stressful situations (3). Surprisingly, IRES-mediated
translation initiation of the c-myc and BiP mRNAs is also enhanced by the poly(A) tail, although PABP
and eIF4G are not involved (12, 13).
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1.1.2 Poly(A) tail in mRNA stability

The poly(A) tail not only enhances translation initiation, but also stabilizes eukaryotic mRNAs in
the cytoplasm. The importance of poly(A) tail in stabilizing mRNAs is reflected by the fact that
shortening of the poly(A) tail (deadenylation) is a prerequisite for the subsequent degradation of most
cytoplasmic mRNAs, regardless of whether they are degraded by the exosome complex from 3’ to 5’or
by the 5’ to 3’ exonuclease Xrn1 following decapping (14, 15) (Fig. 1.2). In mammalian cells
deadenylation is the first step of the decay of both stable messages, such as beta-globin mRNA (16), and
unstable messages, such as mRNAs bearing premature termination codons (PTC) (16), AU-rich
elements (AREs) (17, 18), or miRNA targeting sites (19, 20). Consistently, blocking deadenylation by
knocking down the enzymes catalyzing the deadenylation process (deadenylases) or by over expression
of catalytically inactive deadenylase mutants stabilized mRNAs in mammalian cells (16, 21).

Figure 1.2: Deadenylation is the first step for the degradation of most cytoplasmic mRNAs. After
deadenylation, mRNAs can be degraded in two pathways. In one pathway, the mRNAs are decapped
and then degraded from 5’ to 3’ by Xrn1. In the other pathway, the mRNAs are degraded from 3’ to 5’
by the exosome complex, followed by Dcps-mediated decapping.
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Why is the poly(A) tail so important for mRNA stability? The poly(A) tail and the associated
cytoplasmic PABP may inhibit the 3’ to 5’ mRNA decay pathway simply by blocking the access of
exosome to the mRNA. On the other hand, the 5’ to 3’ mRNA decay pathway can be inhibited by the
poly(A) tail and associated PABP through several mechanisms. For example, in rabbit reticulocyte
lysates, the cooperative interactions between PABPC, eIF4G, and eIF4E significantly strengthened the
interaction between the 5’cap and eIF4E (22), which protects the 5’ cap from the decapping machinery.
PABP can also directly bind to 5’ end of capped mRNA (23), which may help to inhibit decapping as
well. In addition, the poly(A) tail and PABP can inhibit the recruitment of decapping activators such as
the Lsm1-7p complex in yeast (24).
1.2 Major Eukaryotic Deadenylases

The mRNA poly(A) tail can be shortened from 3’ to 5’ by deadenylases in the cytoplasm. Two
deadenylase complexes highly conserved in yeast and human are the PAN and Ccr4-Not complexes.
Other deadenylases, such as PARN and Nocturnin, only exist in higher eukaryotes (25). In the following
section, these deadenylases will be briefly reviewed.

The PAB-dependent poly(A)-specific ribonuclease (PAN) is a heterodimer composed of the Pan3
and Pan2 subunits. Pan2 is a Mg2+-dependent exoribonuclease that releases 5′-AMP from the 3′ end
of poly(A) tails (26, 27). Sequence analysis using Conserved Domain Database (28) showed that Pan2
contains an exonuclease domain, a peptidase domain, and a WD40 domain. The exonuclease domain is
related to the DEDD superfamily and contains four conserved acidic residues that bind the Mg2+ ion
involved in catalysis (29). Pan3 can interact with both Pan2 and PABP (Pab1p in yeast) to recruit Pan2
to the poly(A) tail. In addition, in vitro experiments further showed that PAN is activated by PABP
associated with the RNA substrates (27, 30). Interestingly, the 3’ UTR of yeast MFA2 RNA can also
stimulate the activity of PAN, suggesting that PAN activity is not solely regulated by PABP (26).
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In yeast, Pan3p-Pan2p slowly shortens mRNA poly(A) tails when the major deadenylase Ccr4pPop2p (yeast Caf1p) is deleted (31). Yeast strains harboring deficient Pan2p, Pan3p, or Pab1p (yeast
homolog of PABP), produce mRNAs with longer poly(A) tails (30, 32, 33). In mammalian cells, the
Pan3-Pan2 complex carries out the first phase of deadenylation in the cytoplasm by shortening mRNA
tails from over 200 nt to about 110 nt before the Ccr4-Caf1 deadenylase takes over in the second phase
of deadenylation (16, 19). Pan3 can be phosphorylated (34), but how Pan3 phosphorylation affects its
localization and functions has never been studied.
Yeast Pan3p-Pan2p complex may also play a role in controlling the poly(A) tail length of newly
synthesized mRNAs. It has been reported that partially purified RNA 3′-end processing machinery
from yeast Pan3∆, Pan2∆, or Pan3∆Pan2∆ strains produced transcripts with poly(A) tails longer than
those from a wild-type yeast (35). Within 10 min after addition of purified Pab1p and Pan3p-Pan2p, the
long tails were trimmed to 60-80 residues, a length normally observed in the wild-type extract. The
poly(A) tails were then only slowly shortened over the next 20 min in the reaction. Additionally, in vivo
transcriptional pulse chase experiments showed that the first population of PGK1 transcripts generated
after 4 minutes of galactose-mediated transcription had already undergone Pan3-Pan2 specific
processing, indicating that Pan3p-Pan2p mediated rapid trimming of newly synthesized poly(A) tails in
vivo. Thus, it was proposed that cleaved pre-mRNAs are polyadenylated to a long default length by the
poly(A) polymerase machinery and then quickly deadenylated to a message-specific length by Pan3pPan2p in a Pab1-dependent manner (35). However, this model was challenged by a recent observation
that the poly(A) tail length control of the CYC1 mRNA in an in vitro system was restored by adding the
nuclear poly(A)-binding protein Nab2p even in the absence of Pan3p and Pan2p (36).
In eukaryotes, the major deadenylase activity is carried by the CCR4-NOT complex which contains
the deadenylases Ccr4 and Caf1 and several different NOT (negative regulator of transcription) proteins
(37, 38). Ccr4 contains a leucine-rich repeat (LLR) responsible for interaction with Caf1 (39) and a
ribonuclease domain similar to a family of Mg2+-dependent nucleases related to E. coli exonuclease III.
Yeast Ccr4p exhibited poly(A)-specific 3′ exoribonucleases activity in vitro even in the absence of the
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other subunits of the CCR4-NOT complex (40). Deletion of the CCR4 gene in yeast slowed down the
rate of deadenylation and stabilized mRNAs (31).Unlike the Pan3p-Pan2p complex, the in vitro activity
of yeast Ccr4p can be inhibited by Pab1p (38).

Although Ccr4p is the major deadenylase in the Ccr4-Not complexes in yeast (38), Caf1p (Pop2p) is
also required for efficient mRNA degradation in vivo and has weak deadenylase activity in vitro (41,
42). Like Pan2, Caf1 is a member of the DEDD family of exoribonucleases (43). Human Caf1 has two
paralogs, CNOT7 (hCaf1/Caf1a) and CNOT8 (hPop2/Caf1b), both of which are catalytically active and
required for efficient proliferation of cultured cells (44).

In addition to Ccr4p and Caf1p, the 1-MDa yeast CCR4-NOT complex contains the five NOT
proteins (Not1-5p) as well as Caf40p and Caf130p (45). Deletion of some of the NOT genes in yeast
negatively affected reporter mRNA deadenylation(38). A microarray analysis of mRNAs from yeast
strains with deletion of individual subunits of the Ccr4-Not complex showed that each of the subunits
regulates the expression of a specific group of genes (46). In Drosophila Schneider cells, siRNAmediated silencing of CAF1, NOT1, NOT2, and NOT3, but not CCR4, CAF40, or NOT4, inhibited bulk
deadenylation (47). Interestingly, a yeast decapping factor, Dhh1p, co-immunoprecipitates with Not1p,
suggesting a physical link between deadenylation and decapping machineries (48). (38)
The Ccr4-Not complex can be recruited to specific mRNAs to promote deadenylation of the mRNAs.
TOB, a member of the anti-proliferative BTG (B-cell translocation gene) family, interacts with both
PABP and human Ccr4-Not complex to promote mRNA deadenylation (49). TOB -/- and CNOT7(Caf1)
-/- mice both exhibit increased bone formation (50, 51), suggesting that TOB may recruit the Ccr4-Not
complex to promote the decay of transcripts of genes involved in bone formation. Yeast Vts1p, a
sequence-specific RNA binding protein, interacts with and recruit the Ccr4-Not complex, resulting in
deadenylation of the target mRNAs (52). In mammalian cells, the Ccr4-Not complex also mediates
deadenylation of miRNA targets (19) and mRNAs bearing premature termination codon (PTC) or AUrich elements (AREs) (21).
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PARN, another member of the DEDD nuclease family, is a Mg2+-dependent poly(A)-specific 3’
exoribonuclease inhibited by PABP (53, 54). PARN contains an RNA-binding domain and can bind
both the 5’ cap and the poly(A) tail of mRNAs (55, 56). Interestingly, cap binding enhances the activity
and processivity of PARN (55, 57). Although not found in yeast, PARN is indispensable for
embryogenesis in higher plants and promotes deadenylation of a subset of embryo-specific mRNAs (58).
Some studies, mostly using in vitro decay systems, suggested that mammalian PARN was recruited by
several ARE binding proteins to promote deadenylation of transcripts containing AREs (59-61).
However, direct in vivo evidence showed that unlike Pan2 and Ccr4, PARN did not play a major role in
general deadenylation in mouse NIH 3T3 cells (16).
Nocturnin, a deadenylase related to Ccr4, is unique in that it is encoded by a clock-controlled gene
whose transcription peaks at night in Xenopus retinal phosphoreceptor cells (62) and multiple tissues of
mice (63). Interestingly, Nocturnin knockout mice have defects in lipid metabolism and are therefore
immune to diet-induced obesity and hepatic steatosis(64).
In summary, different deadenylases may function in unique ways, which may be overlapping
sometimes, to shorten mRNA poly(A) tails, leading to translational inhibition and/or degradation of the
mRNAs.
1.3 mRNA Processing Bodies

mRNA processing bodies, also named P bodies or GW bodies, are dynamic cytoplasmic aggregates
of non-translating mRNAs and factors involved in mRNA translational inhibition and decay. Conserved
from yeast to human, P bodies have a diameter of 100-300 nm (65). These membrane-free structures are
mainly anchored to microtubules while constantly moving around in the cytoplasm (66).
Under light microscope, P bodies co-localize with translationally inhibited mRNAs and around 30 or
50 different proteins in yeast and human cells, respectively. These P body proteins are either involved in
mRNA binding (e.g. eIF4E), translational inhibition (e.g. eIF4ET and CPEB1), mRNA decapping (e.g.
Dcp1/2 and Lsm1-7), mRNA 5’ to 3’ degradation (e.g. Xrn1), miRNA-mediated gene silencing (e.g.
Ago1-4 and GW182), or with unknown functions (e.g. ZAR1l) (67, 68). Factors involved in nonsensePage | 8

mediated decay (NMD) were enriched in P bodies when NMD is interrupted in yeast (69) and in
mammalian cells (70). In contrast, most factors involved in mRNA translation, for example PABP,
eIF4G, and ribosome subunits, are normally absent from P bodies (71).
P bodies are sites for mRNA translational inhibition, degradation, and storage (Fig. 1.3). Because P
bodies are ribosome-free, mRNAs in P bodies cannot be translated. Some mRNAs are likely degraded
in P bodies, as inhibition of 5’ to 3’ decay by knocking down Xrn1 increased P body sizes and mRNA
decay intermediates were found in P bodies (72). However, P bodies may also be temporary storage
sites for some mRNAs, as suggested by an observation that a P body mRNA encoding cationic amino
acid transporter 1 (CAT-1) was released from P bodies and subsequently translated when the cells were
subjected to different stresses (73). Therefore, P bodies may function as a “lockup” where the fates of
arrested non-translating mRNAs will be determined.
Although P bodies are conserved in eukaryotes, the physiological significance of their formation is
unknown. One possibility is that by enriching local concentrations of translational inhibitors and mRNA
decay factors, cells can silence unwanted mRNAs more effectively.
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Figure 1.3: Translationally inhibited mRNAs in P bodies can be degraded or released back to the
cytosol for translation. Translation factors such as PABP, eIF4G, and ribosome subunits are released
from mRNAs targeted to P bodies, where these mRNAs can be decapped by Dcp1/2 and degraded from
5’ to 3’ by Xrn1. However, mRNAs in P bodies may also be released to the cytosol and translated.

P body formation involves remodeling and subsequent aggregation of mRNAs and their associated
proteins, together known as messenger ribonucleoproteins (mRNPs). The mRNP remodeling may
include recruitment of translational inhibitors and dissociation of translation activators and translation
machinery. siRNA-mediated knockdown of translational inhibitors such as eIF4E-T and RCK/p54
blocked P body formation (74, 75). Cycloheximide treatment, which inhibits the release of ribosomes
from mRNAs, also abolished P body formation (72, 76). Since deadenylation often leads to mRNA
translational inhibition and mRNA degradation, it is likely that deadenylation is required for P body
formation. In Hela cells, siRNA-mediated knockdown of Ccr4 blocked P body formation (74).
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Surprisingly, deletion of Ccr4 or Pop2(Caf1), the major deadenylases in yeast, only slightly reduced P
body formation (77). However, it is unclear whether deadenylation was completely inhibited by Ccr4
knockdown. The localization and functions of the Pan3-Pan2 complex and Caf1 with regards to P
bodies had not been reported. Therefore the role of deadenylases in P body formation or functions
remained elusive.
The aggregation of the translationally inhibited mRNPs into microscopically visible P bodies seems
to depend on protein-protein interactions, a notion supported by the discovery that most yeast P body
components contain Q/N-rich aggregation-prone regions (78). However, it is not known if the Q/N-rich
regions are also enriched in mammalian P body components.
Although hundreds of studies of P body components have been published, a comprehensive list of
reported P body proteins is lacking, hampering the studying of P bodies as a whole. A comprehensive
list of P body proteins will allow us to predict new P body proteins in mammalian cells, envision how
some of the P body components may function together in the same pathways or processes, and analyze
how P body proteins interact with each other and with other cellular proteins. Thus, such list will lead
to a better understanding of the physiological significance of P-bodies and how P body dynamics may
be controlled.

1.4 Significance of my study

The first part of my study, as described in Chapter 2, was focused on the localization of
deadenylases with regards to P bodies and their functions in P body formation. This study has shed new
light on the mechanisms of P body formation by showing that 1) deadenylase activity of the Ccr4-Caf1
complex is required for mammalian P body formation, and 2) Pan3 is required for P body formation.
The focus of Chapter 3 is functional dissection of Pan3 domains and to test the possible role of Pan3
phosphorylation. This study not only helped us further understand the functions of Pan3 in both
deadenylation and P body formation but also suggested that Pan3 localization and functions might be
regulated by phosphorylation.
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Chapter 4 is a bioinformatics study of all reported P body components, which not only provides a
comprehensive picture of P body organizations and potential functions but also predicts new factors
important for P body dynamics and functions.
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Chapter 2: Deadenylation is Required
for mRNA Processing Body Formation
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2.1. Introduction

Shortening of mRNA poly(A) tails, a process termed deadenylation, is essential for posttranscriptional inhibition of gene expression in eukaryotes, because the poly(A) tail significantly
enhances cytoplasmic mRNA stability and translation initiation. The importance of poly(A) tail in
stabilizing mRNAs is reflected by the fact that deadenylation is the first step for the decay of both stable
and many unstable messages (16-20). The poly(A) tail also enhances translation through the poly(A)
binding protein (PABP) and eIF4G-mediated mRNA circularization, which may facilitate the recycling
of ribosomes from the 3’ end to the 5’ end of the same mRNA (7, 79) and may also enhance the RNA
helicase activity of some translation initiation factors (6).
Deadenylation is catalyzed by deadenylases, such as the highly conserved eukaryotic Pan3-Pan2 and
Ccr4-Caf1 complexes. In the Pan3-Pan2 complex, Pan2 catalyzes deadenylation while Pan3 can interact
with both Pan2 and the PABP to regulate Pan2 activity (27, 30). On the other hand, both Ccr4 and Caf1
have deadenylase activities (37, 38, 42). In yeast, the Ccr4p-Caf1p complex is responsible for major
deadenylation in the cytoplasm (31). In vitro study showed that the deadenylase activity of Ccr4-Caf1
complex is inhibited by PABP (38). In mammalian cells, deadenylation in the cytoplasm are biphasic.
Poly(A) tails are first shortened to about 110 nt by the Pan3-Pan2 complex, followed by a second phase
of deadenylation, during which the Ccr4-Caf1 complex catalyzes further shortening of the poly(A) tail
to oligo(A) (16).
After deadenylation, the mRNA can either be degraded in a 3’ to 5’ direction by the exosome
complex or be decayed from 5’ to 3’ by Xrn1 following decapping by Dcp1-Dcp2 decapping complex
(80). Translationally inhibited mRNAs, translation inhibitors, decapping factors, and the 5’ to 3’
riboexonuclease Xrn1 are found in cytoplasmic foci named mRNA processing bodies or P bodies,
which are membrane-free mRNP aggregates with a diameter of 100-300 nm (65).
P bodies are sites for mRNA translational inhibition, degradation, and storage. Because P bodies are
ribosome-free, mRNAs in P bodies cannot be translated (71). P body mRNAs can be degraded, as
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inhibition of 5’ to 3’ decay by knocking down Xrn1 increased P body sizes and mRNA decay
intermediates were found in P bodies (72). P bodies may also be temporary storage sites for some
mRNAs before they are degraded, as suggested by an observation that an P body mRNA encoding
cationic amino acid transporter 1 (CAT-1) was released from P bodies and subsequently translated when
the cells were subjected to different stresses (73). Therefore, P bodies provide a location where the fates
of non-translating mRNAs (either degradation or release) will be determined pending on the condition.
While decapping and 5’ to 3’ mRNA decay can impact P body formation, the link between
deadenylation and P bodies is unclear. In yeast, both Ccr4p and Pop2p (yeast Caf1) only co-localize
with P bodies in strains where decapping or 5’ to 3’ mRNA decay is inhibited (77). GFP-tagged human
Ccr4 can weakly localize to P bodies in HEK293 cells (76). The Pan3-Pan2 complex was reported to
localize in the cytoplasm in both yeast and mammalian cells (16, 27); however, it was unknown whether
the Pan3-Pan2 deadenylase complex can be found in P bodies.
Deadenylation might be one of the mRNP remodeling steps required for P body formation because it
results in mRNA translational inhibition and mRNA decay, both of which can occur in P bodies. The
observation that siRNA-mediated knockdown of Ccr4 blocked P body formation in Hela cells (74)
supports this notion. However, it remains to be determined whether the deadenylase activity or the
structural entity of Ccr4 is required for P body formation. Besides, deletion of either Ccr4p or Pop2p
(yeast Caf1) only had a small effect on P bodies in yeast (77). Therefore, it remains elusive, especially
in mammalian cells, whether the deadenylase activities of the Ccr4-Caf1 and Pan3-Pan2 complexes are
required for P body formation.
To reveal the link between P body formation and deadenylation and shed new light on the
mechanisms of eukaryotic post-transcriptional gene regulation, I examined cellular localizations of the
Pan3-Pan2 and Ccr4-Caf1 complexes with regards to P bodies, the importance of deadenylase activity
in P body formation, and the underlying mechanisms for the deadenylation-P body formation
relationship in mammalian cells. These experiments revealed that the Pan3-Pan2 complex is enriched in
mammalian P bodies and that Pan3 helps the Ccr4-Caf1 complex localize to P bodies. In addition,
Page | 15

combining in vivo functional analysis performed in our lab, we demonstrated that mammalian P body
formation depends on the deadenylase activity of the Ccr4-Caf1 complex, even when mRNAs are
rendered ribosome-free by puromycin treatment. Taken together, this study provides new insights into
the mechanisms of P body formation and post-transcriptional gene regulation.

2.2. Materials and Methods
2.2.1. Plasmids
To construct a plasmid encoding HA-tagged Pan3 or Caf1, a 2.2-kb Pan3L cDNA amplified by RTPCR from human testis total RNA (Clontech Laboratories, Inc.) or an 855-bp fragment encoding Caf1
amplified from IMAGE clone 6207987 was inserted between the EcoRV and XhoI sites of pSRHisHA
(gift from S. Ohno, Yokohama City University, Yokohama, Japan). The Caf1 cDNA was inserted
between the HindlII and XbaI sites of pcDNA6/V5-HisA (Invitrogen) to generate pcDNA6-Caf1-V5. A
plasmid encoding catalytic inactive Caf1 mutant (D40A) was created using the QuikChange sitedirected mutagenesis kit (Stratagene) with pSR-HA-Caf1 as the template. To construct pcDNA6-Pan2V5, a 3.6-kb Pan2 cDNA was amplified from IMAGE clone 3357890 and inserted between the AflII
and XbaI sites of pcDNA6/V5-HisA (Invitrogen). GFP-Dcp1a and GFP-Ccr4 (gifts from B. Seraphin,
Centre de Génétique Moléculaire, Gif sur Yvette Cedex, France) were described previously (21).
2.2.2. Cell culture and transfection

Either Lipofectamine 2000 (Invitrogen) or FuGENE 6 (Roche) was used for transient transfections.
NIH3T3 B2A2 cells were split to a density of 2.6 × 106/10-cm dish 24 h before transfection in 100
ng/ml tetracycline. 40 μl Lipofectamine 2000 and 1.5 ml Opti-MEM were mixed well and incubated
for 5 min at RT. DNA (1.3 μg of reporter plasmid and 1.3 μg of internal control plasmid, pSV–αglobin–GAPDH) and siRNA (4.86 μg of nonspecific siRNA or Pan3 siRNA, or 2.43 μg Caf1 siRNA
plus 2.43 μg Pop2 siRNA [SMARTpool; Thermo Fisher Scientific]) were diluted into 1.5 ml OptiPage | 16

MEM, added to the Lipofectamine 2000 mixture, and incubated at RT for 25 min. The final mixture was
then added to the cells in a 10-cm dish and incubated at 37°C (5% CO2). Cells were split 18 h later into
6-cm dishes (1.5 × 106/6 cm dish) and incubated at 37°C (8% CO2) for 24 h. When using FuGENE 6,
NIH3T3 B2A2 cells were split to a density of 0.65 × 106/6-cm dish 24 h before transfection in the
presence of 50 ng/ml tetracycline. 6.9 μl FuGENE 6 was diluted in 100 μl DME and mixed with 2.3
μg DNA containing 0.055 μg of reporter plasmid, 0.11 μg of internal control plasmid, and 2.13 μg
of DNA encoding HA-tagged proteins. The mixture was incubated at RT for 25 min, added to the
culture dish, and incubated at 37°C (8% CO2) for 42 h. Time-course experiments using the Tet-off
system for transcriptional pulsing were performed as described previously (21, 81).
2.2.3. Western blot analysis

Cytoplasmic and nuclear lysates were prepared as described previously (82). Total cell lysates (5–40
μg) were resolved on a 7 or 10% SDS-polyacrylamide gel and analyzed using an ECL Western blotting
kit (GE Healthcare). The PVDF blots were probed with specific antibodies as indicated in each figure
and detected with SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific).
Membranes were incubated with one of the primary antibodies at the indicated dilution: HRPconjugated monoclonal Anti-V5 antibody at 1:5,000 (Invitrogen); HRP-conjugated monoclonal anti-HA
antibody at 1:1,000 (Roche); rat anti-HA monoclonal antibody at 1:4,000 (Roche); mouse anti–αtubulin monoclonal antibody at 1:10,000 (Sigma-Aldrich); rabbit anti-Dcp1a serum at 1:4,000 (Bethyl
Laboratories, Inc. or gift from S. Ohno); rabbit anti-Rck/p54 serum at 1:1,000 (Bethyl Laboratories,
Inc.); mouse monoclonal antibody against GAPDH at 1:10,000 (Research Diagnostics, Inc.); and mouse
antibody against lamin A/C at 1:1,000 (Santa Cruz Biotechnology, Inc.). Rabbit anti-PABP antibody
(gift from R. Lloyd, Baylor College of Medicine, Houston, TX) was used at a 1:4,000 dilution. To
detect endogenous Caf1, Pan2, and Pan3 in mouse NIH3T3 or monkey COS7 cells, the corresponding
polyclonal antibodies were generated in rabbits immunized with gene-specific peptides using the custom
antibody service from Bethyl Laboratories, Inc. Affinity-purified anti-peptide antibodies were used at
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the following dilutions: rabbit anti-Pan3 peptide antibody at 1:2,000; rabbit anti-Caf1 peptide at 1:1,000;
or rabbit anti-Pan2 peptide at 1:2,000. HRP-conjugated donkey anti–rabbit IgG antibodies (1:4,000; GE
Healthcare) or goat anti–mouse (1:5,000; Bio-Rad Laboratories) were used as secondary antibodies for
detection with a chemiluminescence reagent (peroxide/luminol enhancer; Thermo Fisher Scientific) (21).
2.2.4. Immunofluorescence staining and microscopy

NIH3T3 cells were seeded in 6-well plates at a density of 0.4 × 106 cells per well, 24 h before
transfection using Lipofectamine 2000 (Invitrogen). At 22–26 h after transfection, cells were reseeded
to slide chambers (BD Biosciences) and incubated overnight. For cycloheximide, puromycin, or arsenite
treatment, cells were incubated in media containing either 7.5 μg/ml cycloheximide (Sigma-Aldrich)
for 2 h, 100 μg/ml puromycin (Sigma-Aldrich) for 1 h, or 0.3 mM sodium arsenite (Sigma-Aldrich) for
1 h before fixation. Cells in the slide chambers were fixed for 10 min each with 3.7% (wt/vol) PFA
(Sigma-Aldrich) in PBS and then with cold methanol, followed by a 10-min incubation in 0.2% (vol/vol)
Triton X-100 in PBS. Each microgram of Zenon-labeled antibodies (see third paragraph in this section)
was diluted in 500 μl of 1% BSA in PBS and incubated with the fixed slides. After incubating for 1 h
at RT and washing, the slides were fixed again in 3.7% PFA. For indirect immunofluorescence
microscopy, all of the primary and secondary antibodies, except the mouse anti-myc serum, were
diluted 1:1,000 with 1% (wt/vol) BSA in PBS. Endogenous Pan2 was detected using rabbit anti-Pan2
labeled with Zenon 555 rabbit IgG labeling reagent. Endogenous Dcp1a, Xrn1, or Pan3 was detected
using rabbit anti-Dcp1a, anti-Xrn1, or anti-Pan3 labeled with Zenon 488 rabbit IgG labeling reagent.
HA-tagged Pan3, Ccr4, or Caf1 was detected using rat anti-HA monoclonal antibody and Alexa Fluor
350 goat anti–rat IgG. HA-Pan2 or V5-tagged proteins were detected using rat monoclonal anti-HA or
mouse monoclonal anti-V5 and Alexa Flour 555 goat anti–rat IgG. Rabbit anti-Xrn1 antibody was a gift
from J. Lykke-Andersen (University of Colorado at Boulder, Boulder, CO), human anti-GW182
antiserum was a gift from M.J. Fritzler (University of Calgary, Calgary, Canada), rabbit anti-G3BP1
was a gift from R. Lloyd (Baylor College of Medicine, Houston, Texas), and rabbit anti-Dcp1a antibody
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was a gift from S. Ohno (Yokohama, Japan). The mouse anti-myc monoclonal antibody from culture
medium collected from anti-myc monoclonal antibody secreting hybridoma cells (American Type
Culture Collection) was used at 1:50 dilution. After incubation with the indicated primary
antibodies/sera, cells were washed three times in PBS for 5 min and incubated with fluorescently
labeled secondary antibodies (Invitrogen) as indicated in the figures. Fluorescence mounting medium
with or without DAPI was added.
Images were obtained at RT by optical z-sectioning (20 sections in total, 0.2-μm-space between
sections) using an objective lens (100×/1.35 NA; Olympus) of a deconvolution microscope system
(DeltaVision) containing an inverted microscope (IX70; Olympus). Immersion oil (n = 1.514) was from
Applied Precision, LLC. Images were captured using a digital camera (Coolsnap HQ; Roper Scientific).
Stacks of 20 images were projected as a single 2D picture using softWoRx Explorer (version 3.3.6;
Applied Precision, LLC). The RGB colors of the resulting pictures were separated using Photoshop CS
(Adobe).
When two different primary antibodies raised in rabbits were used together to visualize P-bodies, the
following procedure was used. One μg of rabbit antibody was incubated for 5 min at RT with 5 μl
Zenon rabbit IgG labeling reagent, either Alexa Flour 488- or 555-labeled Fab fragment (Invitrogen).
The labeled Fab fragment was bound to the Fc portion of the rabbit IgG, and excess Fab fragment was
neutralized by the addition of 5 μl of nonspecific rabbit IgG, which prevented cross-labeling of the Fab
fragment when two rabbit antibodies were used. After a 5-min incubation at RT, the labeled antibodies
were used for staining in combination with each other or with labeled secondary antibodies specific for
other species. To analyze the changes in P-body number and size after Pan3 knockdown, 87 cells
transfected with control nonspecific siRNA and 91 cells transfected with Pan3 siRNA were analyzed
using ImageJ software (pixel range for particle brightness between 40 and 215; National Institutes of
Health). Dcp1a particles with values >50 square pixels were considered above background staining and
were selected for P-body analysis (21).
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2.3. Results
2.3.1. Both Pan2 and Pan3 co-localize with P bodies in mammalian cells.

To reveal the link between deadenylation and P bodies, we first determined the subcellular
localization of Pan2 and Pan3, the factors involved in initiating mammalian mRNA deadenylation (16),
with regards to P-bodies in mammalian cells. The well-characterized P-body components Dcp1a and
Xrn1 are used as markers to visualize P bodies by immune-fluorescence microscopy (83). The results
show that cytoplasmic foci detected by an anti-Pan2 antibody co-localize with P bodies marked by
endogenous Dcp1a (Fig. 2.1 A) in NIH 3T3 cells. Cycloheximide treatment, which blocks P body
formation by inhibiting the release of ribosomes from mRNAs (84), also blocked Pan2 foci
formation(Fig. 2.1 B). Endogenous Pan2 foci also co-localize with both endogenous Dcp1a foci and
endogenous Xrn1 foci in COS7 cells (Fig. 2.1 C). These results indicate that Pan2 is a component of P
bodies in mammalian cells.

Page | 20

Figure 2.1: Endogenous Pan2 is enriched in P bodies in both NIH 3T3 cells and COS7 cells.
(A) Immuno-fluorescence
fluorescence staining showing endogenous Pan2 colocalizes with Dcp1a in P bodies in
NIH 3T3 cells. (B)) The Pan2 foci in NIH 3T3 cells are disassembled by cycloheximide treatment, as
expected for P bodies. (C)) Pan2 foci colocalize with P
P-bodies detected with anti-Dcp1a
Dcp1a (top) or antianti
Xrn1 (bottom) in COS7 cells. ((The experiments were repeated once.)
Courtesy to The Journal of Cell Biology (21).
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Next we checked if Pan3, the other subunit of the Pan3-Pan2 complex, also co-localizes with P
bodies. Due to the lack of an anti-Pan3 antibody suitable for immune-fluorescence microscopy, a
plasmid encoding HA-tagged Pan3 (HA-Pan3) was delivered into NIH 3T3 cells through transient
transfection and an anti-HA antibody was used to study the sub-cellular localization of HA-Pan3. As
expected, HA-Pan3 also co-localizes with P bodies labeled with either anti-Dcp1a or GFP-Dcp1a in
NIH 3T3 cells (Fig. 2.2 A). Since Pan3 can also interact with PABP (27, 30), which was not found in P
bodies previously (71), we checked if PABP can be enriched in HA-Pan3 foci. We found that neither
ectopically expressed myc-tagged PABP (Fig. 2.2 B) nor endogenous PABP (data not shown) is
concentrated in HA-Pan3 foci. Moreover, the HA-Pan3 foci are not stress granules, as they do not colocalize with the stress granule marker G3BP-1 (71), no matter whether the cells were treated with
arsenite to induce stress granule formation (Fig. 2.2 C, top) or not (Fig. 2.2 C, bottom). Collectively,
our results identify both Pan2 and Pan3 as two new components of P bodies in mammalian cells.
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Figure 2.2: PABP is not found in HA
HA-Pan3
Pan3 foci, which coloclaize with P bodies but not stress
granules. (A) Immuno-fluorescence
fluorescence staining showing ectopically expressed HA
HA-tagged
tagged Pan3
colocalizess with endogenous Dcp1a (top) and EGFP
EGFP-tagged
tagged Dcp1a (bottom) in P bodies of NIH 3T3
cells. (B) HA-Pan3
Pan3 foci do not colocalize with myc
myc-PABP. (C) HA-Pan3
Pan3 foci do not colocalize with the
stress granule marker G3BP-11 in NIH 3T3 cells with (top) or without (b
(bottom)
ottom) arsenite treatment. (The
experiments
xperiments were repeated at least once.)
Courtesy to The Journal of Cell Biology (21).
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2.3.2. Pan3 is an essential P body component that can recruit the non-essential P body component
Pan2 to P bodies

Since both Pan3 and Pan2 are P body components, we next determined whether they are essential
for P body formation in NIH 3T3 cells. To this end, NIH 3T3 cells were transfected with either nonspecific siRNA (NS siRNA), Pan3 specific siRNAs, or Pan2 specific siRNA, followed by immunofluorescence microscopy and particle analysis using the free NIH software ImageJ (85). siRNAmediated Pan3 knockdown in NIH 3T3 cells dramatically decreased the number and average size of P
bodies in cells labeled with anti-RCK/p54, another popular P body marker (Fig. 2.3). This observation
suggests that Pan3 is an essential component of P bodies. On the other hand, siRNA-mediated Pan2
knockdown had little effect on P body formation (Fig. 2.4 A&B). Moreover, overexpression of a
catalytic mutant of Pan2 did not block P body formation (Fig. 2.4 C). These observations suggest that
Pan2 is not essential for P body formation.
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Figure 2.3: siRNA-mediated
mediated Pan3 knockdown inhibits P body formation in NIH 3T3 cells.
fluorescence staining using
(A)) Western Blotting showing knockdown of Pan3 by siRNA. ((B) Immuno-fluorescence
anti-RCK/p54
RCK/p54 to detect P bodies in NIH 3T3 cells transfected with either Pan3 siRNA or nonspecific
siRNA. (C)) Analysis of P body numbers and average sizes in NIH 3T3 cells transfected with either
Pan3 siRNA or nonspecific siRNA
siRNA. The experiment was repeated once.
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C.

Figure 2.4: siRNA-mediated
mediated Pan2 knockdown has little effect on P body formation in NIH 3T3
cells.
(A)) Western Blotting showing knockdown of Pan2 by siRNA. ((B) Immuno-fluorescence
fluorescence staining using
anti-RCK/p54
RCK/p54 to detect P bodies in NIH 3T3 cells transfected with either Pan2 siRNA or nonspecific
siRNA.(C) Overexpression of a catalytic mutant of Pan2 did not block P body formation. The
experiment
xperiment was repeated once.
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The above results are consistent with the following observations. Firstly, HA-Pan3 localizes to P
bodies when it is ectopically expressed alone (Fig. 2.2 A), suggesting that Pan3 can associate with P
bodies without a coordinated expression of Pan2. Secondly, ectopically expressed Pan2 did not form
any cytoplasmic foci when expressed alone (Fig. 2.5 A), but did co-localize with P bodies when coexpressed with HA-Pan3 (Fig. 2.5 B), indicating that Pan2 is recruited to P bodies through its
interaction with Pan3. Together, these results indicate that Pan3 is an essential P body component that
can recruit the non-essential P body component Pan2 to P bodies.
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Figure 2.5: HA-Pan3
Pan3 helps ectopically expressed Pan2 to colocalize with P bodies.
(A) Ectopically expressed HA--tagged Pan2 (top) and V5-tagged
tagged Pan2 (bottom) cannot
can
be
enriched in P bodies. (B) V5-tagged
tagged Pan2 is enriched in P bodies when HA
HA-tagged
tagged Pan3 is
co-expressed. The experiment
xperiment was repeated twice.
Courtesy to The Journal of Cell Biology (21).
.
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2.3.3. HA-Pan3 helps co-expressed Caf1 and Ccr4 to be enriched in P bodies.

After the first phase of deadenylation by the Pan3-Pan2 complex, the Ccr4-Caf1 deadenylase
complex catalyzes the second phase of deadenylation (16). Since Ccr4 weakly localize to P bodies in
HEK293 cells (76), we asked whether Caf1, which forms a complex with Ccr4, also co-localizes with P
bodies. Our results show that ectopically expressed Caf1 was not enriched in P bodies in NIH 3T3 cells,
regardless of whether it was expressed alone (Fig. 2.6 A, top) or together with ectopic Ccr4 (Fig. 2.6 A,
bottom). GFP-tagged Ccr4 also did not form any foci co-localizing with P bodies in NIH 3T3 cells (Fig
2.6 C). Our results are consistent with the observations that yeast Ccr4p and Caf1p (Pop2p) normally do
not co-localize with P bodies (77). Because the Pan3-Pan2 complex, which catalyzes the first phase of
deadenylation, is in P bodies, we suspected that co-expressed HA-Pan3 can help the second phase
deadenylases Ccr4 and Caf1 to localize to P bodies. Indeed, both V5-tagged Caf1 and GFP-tagged Ccr4
were enriched in P bodies when HA-Pan3 was co-expressed (Fig. 2.6 B and D). The effect of coexpressed HA-Pan3 on Caf1-V5 and GFP-Ccr4 localizations is not likely due to non-specific
recruitment of co-expressed proteins by HA-Pan3 foci, because co-expressed myc-PABP was not
enriched in HA-Pan3 foci (Fig 2.2 B).
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Figure 2.6: HA-Pan3
Pan3 helps ectopically expressed Caf1 and Ccr4 to colocalize with P bodies.
(A) Ectopically expressed V5-tagged
tagged Caf1 (top) can
cannot
not be enriched in P bodies, even when HAHA
tagged Ccr4 is co-expressed
expressed (bottom). ((B) V5-tagged Caf1 is enriched in P bodies when HAHA
tagged Pan3 is co-expressed. (C
C) GFP-tagged
tagged Ccr4 can hardly be enriched in P bodies in NIH 3T3
cells. (D) GFP-Ccr4
Ccr4 can be enriched in P bodies when co
co-expressed with HA-tagged
tagged Pan3. The
experiment
xperiment was repeated twice.
Courtesy to The Journal of Cell Biology (21).
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2.3.4. Deadenylase activity of the Ccr4-Caf1 complex is required for P body formation

Both Caf1 and Ccr4 can be enriched in P bodies when co-expressed with HA-Pan3. Since siRNAmediated knockdown of Pan3 inhibited P body formation in NIH3T3 cells (21) and Ccr4 knockdown
was reported to block P body formation in Hela cells (74), we asked if Caf1 is also required for P body
formation. siRNA-mediated Caf1 knockdown blocked P body formation (Fig 2.7), indicating that Caf1
is important for the formation of microscopically visible P bodies.
Next, we asked if the deadenylase activity of the Ccr4-Caf1 complex is required for P body formation.
To this end, we created a catalytically inactive mutant of Caf1 by changing a critical aspartate residue
necessary for metal binding and Caf1 nuclease activity to alanine by site-directed mutagenesis (29).
While ectopically expressed wild-type Caf1 promoted deadenylation and subsequent decay of the
reporter BBB mRNA (Fig. 2.8 C), mutant Caf1 expression almost completely blocked reporter mRNA
deadenylation (Fig. 2.8 D). The reporter mRNA was still degraded, although at a much slower rate,
suggesting that mRNA can be degraded in deadenylation-independent manner when deadenylation is
blocked. The catalytically mutant, but not the wild-type, Caf1 also blocked P body formation in NIH
3T3 cells (Fig. 2.8 E and F) and COS7 cells (data not shown). Interestingly, co-expression of wild-type
Ccr4, but not catalyticaly mutant Ccr4, with Caf1 mutant restored fast deadenylation of the BBB
reporter mRNA (Fig. 2.9 B), suggesting that the deadenylase activity of Ccr4 is complementary to Caf1
in the Ccr4-Caf1 complex. Concomitantly, co-expressed wild-type Ccr4, but not catalytically mutant
Ccr4, released the blockage of P body formation by Caf1mt (Fig. 2.9 D and E). Collectively, our
observations provided strong evidence that the deadenylase activity of the Ccr4-Caf1 complex is
required for P body formation.
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mediated Caf1 knockdown blocks P body formation in NIH 3T3 cells.
Figure 2.7: siRNA-mediated
fluoresence staining showing the
(A)) Western showing the knockdown of Caf1 by siRNA. (B) Immuno-fluoresence
effect of siRNA-mediated
mediated Caf1 knockdown on P body formation. The experimentss were repeated three
times.
Courtesy to The Journal of Cell Biology (21).
.

Page | 32

Figure 2.8: Overexpressed Caf1 catalytic mutant, but not wild
wild-type
type Caf1, inhibits both P body
formation and deadenylation.
HA-tagged Caf1 and Caf1 mutant. (B-D)) Northern blots howing
(A) Western showing the expression of HA
the effects of overxpression of nothing ((B), wild-type (C), or mutant (D)) Caf1 on the deadenylation and
decay of the BBB reporter mRNA. ((E-F) Immuno-fluoresence staining showing ectopically expressed
HA-tagged Caf1 (E)) or Caf1 catalytic mutant ((F) on P body formation. The experiment
xperiment was repeated
twice.
Courtesy to The Journal of Cell Biology (21).
Northern analysis (B,C,D) was performed by Wenmiao Zhu.
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Figure 2.9: P body formation is restored when the blockage of deadenylation is released by coco
expressed Ccr4.
(A)) Western blotting showing the expression of Caf1 mutant and Ccr4 or Ccr4 mutant. (B-C) Northern
blots showing the effects of overxpression of both Caf1 mutant and wild
wild-type
type Ccr4 (B)
( or Ccr4 catalytic
mutant (C)) on the deadenylation and decay of the BBB reporter mRNA. ((D-E) Immuno-fluoresence
Immuno
staining showing
owing ectopically expressed Caf1 catalytic mutant and wild
wild-type (D)) or catalytically mutant
Ccr4 (E)) on P body formation. The experiment was repeated twice.
Courtesy to The Journal of Cell Biology (21).
Northern blot analysis (B) and (C) was performed by Wenmiao Zhu and Dr. Nader Ezzeddine,
respectively.
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2.3.5. Requirement of deadenylation for P body formation cannot be bypassed by puromycin
treatment that removes ribosomes from mRNAs

Why is P body formation deadenylation-dependent? Since only ribosome-free mRNAs can enter P
bodies and translation of most mRNAs is inhibited by deadenylation (9), it is likely that the requirement
of deadenylation for P body formation is simply because deadenylation helps the mRNAs to become
ribosome-free. To test this idea, puromycin was used to release ribosomes from cellular mRNAs (86)
while deadenylation was inhibited either by overexpression of Caf1 catalytic mutant or siRNA-mediated
knockdown of Caf1 in NIH 3T3 cells. Strikingly, puromycin treatment failed to induce P-body
formation when deadenylation is inhibited (Fig 2.10), although puromycin indeed promoted P body
formation in cells where deadenylation is not impaired. Therefore, deadenylation is required for mRNAs
to enter P bodies even if the mRNAs are ribosome-free. In other words, the shortening of poly(A) tails
per se, not only the release of ribosomes from mRNA, is one of the necessary remodeling steps for
mRNPs to form P bodies.
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Figure 2.10: Puromycin treatment cannot induce P body formation when HA
HA--Caf1 mt is over
expressed or Caf1 is knocked down by siRNAs.
(A) Indirect immuno-fluorescence
fluorescence staining showing the effects of puromycin treatment on
untransfected cells and cells expressing either wild
wild-type
type (upper panel) or catalytically mutant (lower
panel) Caf1. (B)) Western blotting showing siRNA
siRNA-mediated Caf1 knockdown. (C)) Indirect immunoimmuno
fluorescence staining showing the effects of puromycin treat
treatment and/or siRNA-mediated
mediated Caf1
knockdown on P body formation detected by GW182 antibody. The experiment
xperiment was repeated twice.

Courtesy to The Journal of Cell Biology (21).
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2.4. Discussion

2.4.1. Deadenylation may also occur in P bodies

Both the Pan3-Pan2 and the Ccr4-Caf1 deadenylase complexes can be enriched in P bodies of
mammalian cells (Figs. 2.1, 2.2 & 2.6), suggesting that deadenylation may also occur in P bodies. In
yeast, Ccr4p and Pop2p (yeast Caf1) co-localize with P bodies in strains where decapping or 5’ to 3’
mRNA decay is inhibited (77). It is possible that the Ccr4-Caf1 complex transits through P bodies
quickly in yeast and therefore is only enriched in P bodies under special conditions. Moreover, at least
some mRNAs in P bodies still have poly(A) or oligo(A) tails. Poly(A)+ transcripts can be detected in
yeast P bodies during glucose deprivation and in stationary phase (87). In human cells, the CAT-1
mRNA can be released from P bodies and recruited to polysomes for translation in response to different
types of stresses (73). It is possible that some translationally inhibited poly(A)+ RNAs are targeted to P
bodies for temporary storage, where they can either be deadenylated, decapped, and subsequently
degraded, or released for translation before complete deadenylation.
2.4.2. Deadenylation factors have different roles in P body formation

Our observations also indicate that Pan3, Pan2, and the Ccr4-Caf1 complex play different roles in P
body formation. Pan3, which interacts with both PABP and Pan2, is essential for P body formation, as
siRNA-mediated Pan3 knockdown greatly decreased P body numbers and sizes in NIH 3T3 cells (Fig.
2.3). Co-expressed HA-Pan3 also helps ectopically expressed Pan2, Ccr4, and Caf1, but not PABP, to
be enriched in P bodies (Fig. 2.5 & 2.6). Interestingly, the deadenylase Pan2 seems to be dispensable for
P body formation, although it interacts with Pan3 and colocalizes with P bodies. siRNA-mediated knock
down of the deadenylase Pan2 had little effect on P body formation (Fig. 2.4 A&B), which is consistent
with the observation that over expression of catalytically mutant Pan2 had no effect on P bodies in NIH
3T3 cells (Fig. 2.4 C). Our results suggest that Pan3 has functions independent of Pan2 in P body
formation, which will be addressed in Chapter three.
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The deadenylase activity of the Ccr4-Caf1 complex is essential for P body formation in mammalian
cells. siRNA-mediated knockdown of Caf1 inhibited P body formation in NIH 3T3 cells (21) and Ccr4
knockdown blocked P body formation in Hela cells (74). Over expression of catalytic mutant of either
Caf1 or Ccr4 inhibited deadenylation (Fig. 2.8 & (16)) and blocked P body formation (Fig. 2.8 and data
not shown). Moreover, restoring deadenylation allowed P body formation (Fig. 2.9). Collectively, these
observations indicate that P body formation in mammalian cells requires the deadenylase activity of the
Ccr4-Caf1 complex.
It is noteworthy that in yeast deletion of either Ccr4p or Pop2p (yeast Caf1) only had a small effect
on P bodies (77), even though the Ccr4p-Pop2p complex is the major deadenylase in yeast. This
discrepancy suggests different mechanisms for P body formation in yeast and mammalian cells. Indeed,
yeast, but not human, P body components are more likely to contain Q/N-rich aggregation-prone regions
(78), which may help the aggregation of associated mRNPs into P bodies.
2.4.3. Deadenylation per se, and not just dissociation of ribosomes from mRNAs, is required for
mammalian P body formation

Since mRNAs need to be ribosome-free to form P bodies (72, 76) and the poly(A) promotes
translation initiation, it is likely that deadenylation allows P body formation by rendering the mRNAs
ribosome-free. To test this possibility, cells were treated with puromycin to release ribosomes from
mRNAs while deadenylation was inhibited either by overexpression of Caf1 mutant or siRNA-mediated
knockdown of Caf1. To our surprise, P body formation was still blocked in cells treated with puromycin
when deadenylation was inhibited. Our observation indicates that the importance of deadenylation in P
body formation cannot be simply explained by the inhibitory effect of deadenylation on recruitment of
ribosomes to the mRNAs.
Another reason why deadenylation is required for P body formation might be that deadenylation
helps removal of the translation activators PABP and eIF4G from the mRNAs. eIF4G can
simultaneously interact with both the cap-binding protein eIF4E and the poly(A) tail-binding protein
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PABP to circularize poly(A)+ mRNAs, forming a closed-loop conformation that may inhibit P body
localization and degradation. Indeed, neither PABP nor eIF4G is enriched in P bodies. In addition,
deadenylation may promote the interaction between mRNAs and the Lsm1-7 complex, a decapping
activator that prefers to bind deadenylated mRNAs (88). In summary, my experiments demonstrate a
pivotal role of deadenylation in P body formation.

2.4.4. A working model linking deadenylation and P body formation

Based on previous and current observations, the following working model is proposed to link
deadenylation and P body formation in mammalian cells (Fig. 2.11). The PABPs on mRNA poly(A) tail
interact with Pan3 to recruit the deadenylase Pan2, initiating the first phase of deadenylation. After the
poly(A) tail is significantly shortened by Pan2, the remaining PABPs associated with the Poly(A) tail is
less effective in inhibiting the deadenylase activity of the Ccr4-Caf1 complex, allowing the second
phase of deadenylation to occur. During the first phase and/or early second phase of deadenylation,
PABP, eIF4G, and ribosomes dissociate from the mRNPs and the mRNPs can loosely attach to P bodies.
It may be speculated that these loose mRNPs constitute the outer layer of P bodies. At this stage, the
mRNPs can either be released from P bodies for translation or be further deadenylated by the Ccr4-Caf1
complex, which results in recruitment of the Lsm1-7 complex. The resultant mRNPs then form the core
of P bodies and its mRNA component can be decapped and degraded within P bodies. One possibility is
that when the deadenylase activity of the Ccr4-Caf1 complex is inhibited, the mRNPs cannot form the
cores of P bodies, therefore P body formation is inhibited.
The proposed model helps explain why the deadenylation complexes co-localize with P bodies, why
deadenylation is required for P body formation, why PABP, eIF4G, and ribosomes are not enriched in P
bodies, and why some mRNAs released from P bodies can still be translated.
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Figure 2.11: A model linking deadenyl
deadenylation and P body formation.

The PABP proteins on mRNA poly(A) tail interact with Pan3 to recruit the deadenylase Pan2,
initiating the first phase of deadenylation. After the poly(
poly(A)
A) tail is significantly shortened by
Pan2, the remaining PABP proteins associated with the Poly(A) tail is less effective in
inhibiting the deadenylase activity of the Ccr4
Ccr4-Caf1
Caf1 complex, allowing the second phase of
deadenylation to occur. During the firs
firstt phase and/or early second phase of deadenylation,
PABP, eIF4G, and ribosomes dissociate from the mR
mRNP
NP and the mRNP loosely attach to P
bodies, forming the outer layer of P bodies. At this stage, the mRNP can either be released from
P bodies for translation or be further deadenylated by the Ccr4
Ccr4-Caf1
Caf1 complex, which results in
recruitment of the Lsm1-77 complex. The resulting mRNP now form the core of P bodies and its
mRNA component can be decapped and degra
degraded within P bodies.
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Chapter 3: Potential Phosphorylation of
Pan3 N-terminal Domain in Regulating
Pan3 Localization and Functions
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3.1. Introduction

The Pan3-Pan2 deadenylase complex is conserved from yeast to human. In yeast, Pan3p-Pan2p
slowly shortens mRNA poly(A) tails when the major deadenylase Ccr4p-Pop2p is deleted (31). In
mammalian cells, the Pan3-Pan2 complex carries out the first phase of deadenylation in the cytoplasm
by shortening mRNA tails from over 200 nt to about 110 nt before the Ccr4-Caf1 deadenylase takes
over in the second phase of deadenylation (16, 19).
The N-terminal domain of Pan3 interacts with the cytoplasmic PABP, while the C-terminal domain
of Pan3 binds deadenylase Pan2 (27, 30). By simultaneously interacting with both PABP and Pan2,
Pan3 recruits the Pan2 to its substrate, the mRNA poly(A) tail. Interestingly, yeast Pan2p substrate
specificity is determined by Pan3p and Pab1p (homolog of PABP), as non-poly(A) sequences bound by
Pab1p can also be degraded by purified Pan3p-Pan2p (26). Although it is clear that Pan3 recruits Pan2
to its substrates, Pan3 may also plays other roles in regulating Pan2 activity.
Mammalian Pan3 and Pan2 are enriched in cytoplasmic mRNA processing bodies (P bodies) and
Pan3 is required for P body formation in NIH 3T3 cells (21). Yeast Pan3p and Pan2p also form
cytoplasmic foci (36), although it is unclear whether those foci co-localize with P bodies. The colocalization of Pan3-Pan2 with P bodies is independent of PABP, because PABP is not enriched in
mammalian P bodies even when Pan3 is over expressed (21, 71). Ectopically expressed Pan3 helps cotransfected Pan2 to enter P bodies (21), but it’s unclear whether Pan3’s P body localization is Pan2dependent.
Interestingly, Pan3 can be phosphorylated at multiple sites. Yeast Pan3p is a substrate of the Pho85Pcl1 cyclin-dependent kinase (89), a functional homolog of mammalian CDK5. Yeast Pan3p can also be
phosphorylated at T57 and S252 upon DNA damage (90). Mouse Pan3 is phosphorylated at T41 (91),
while human Pan3 in Hela cells is phosphorylated at S208 during G1 phase of cell cycle (34). It should
be noted that all of the reported phosphorylation sites are within the N-terminal domain of Pan3. How
phosphorylation affects Pan3’s functions and localizations is unknown.
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In this study, I generated a series of Pan3 truncation mutants to study the interplay among Pan3Pan2 interaction, P body localization, and mRNA degradation. Mutations in Pan3 N-terminal domain
mimicking hyperphosphorylation or hypophosphorylation were made to study the effects of Pan3 Nterminal domain phosphorylation on Pan3 localization and function.
3.2. Materials and Methods
3.2.1 Plasmids.
Construction of pSR-HA-hPan3 was described in Chapter 2. pSR-λN-HA-hPan3 was constructed
by ligating synthesized λN DNA flanked by NheI and MluI sticky ends with NheI and MluI-digested
PCR product using pSR-HA-hPan3 as template and two primers that amplify HA-Pan3 sequence and
the plasmid backbone. The forward and reverse sequences of the NheI- λN-MluI fragment are
CTAGCATGAACGCACGAACACGAC GACGTGAGCGTCGCGCTGAGAAACAAGCTCAAT
GGAAAGCTGCAAAC and CGCGTGTTTGCAGCTTTCCATTGAGCTTGTTTCTCAGCGCGACG
CTCACGTCGTCGTGTTCGTGCGTTCAT, respectively. The forward and reverse primers for
amplifying HA-Pan3 sequence and the plasmid backbone are actagt(adaptor)ACGCGT(MluI site)GGTTCATACCCATACGATGTTCCAG and actagt(adaptor)GCTAGC(NheI site)-ATGAGAACCCC
GCATGGTG.
pSR-HA-hPan3(166-741), pSR-HA-hPan3(288-741), pSR-HA-hPan3(354-741), pSR-HA-hPan3(1353), and pSR-HA-hPan3(1-588) were generated by ligating XmaI and XhoI-digested PCR-amplified
hPan3 cDNA partial fragments with the larger fragment of XmaI and XhoI-digested pSR-HA-hPan3
plasmid. hPan3(166-741) was PCR amplified from the pSR-HA-hPan3 plasmid template using primers
TTCCCGGGTCTGCCTTCTCTCAAGTTTTCTCTCACC and
GCTCGAGTCACAACTGACCATTTGC, hPan3(288-741) using primers
TTCCCGGGATGCAACCGAAAGCAAACGCAC and GCTCGAGTCACAACTGACCATTTGC,
hPan3(354-741) using primers aattatCCCGGG-GGATATATTACATCTTGCTACAAAGCTG and
ATCGCTACTTAGCTAGAGCTCG, hPan3(1-353) using primers
ATGTTCCAGATTACGCTTTAATTAAGC and
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aattatCTCGAGAAAATTACTTGATTTCTGTATCCGGTTG, and hPan3(1-588) using
ATGTTCCAGATTACGCTTTAATTAAGC and aataatCTCGAGAGTCAACAAATACAAAATCAGATTCTTCAG. pSR-HA-hPan3(1-353, 589-741) was created using
the Quickchange kit (Stratagene) and primers that allow PCR amplification of the whole pSR-HAhPan3 plasmid except the cDNA encoding aa 354-588 of hPan3. The sequences of the Quickchange
primers are GGATACAGAAATCAAGTAATGACCAAAACAGGATGCGAAGTG and
CACTTCGCATCCTGTTTTGGTCATTACTTGATTTCTGTATCC. pSR- λN-HA-hPan3(166-741),
pSR- λN-HA-hPan3(288-741), pSR- λN-HA-hPan3(1-353), and pSR- λN-HA-hPan3(1-588) and
pSR- λN-HA-hPan3(1-353, 589-741) were created similarly using pSR- λN-HA-hPan3 as template.

pSR-λN-HA-Pan(PM11) and pSR-λN-HA-Pan(NP11) were created in three steps. The first step
was creation of a λN-HA-hPan3(PCD) mutant with a truncation in the potentially phosphorylated
region which results in a unique recognition site for the blunt end restriction enzyme MscI. This was
done using the Quickchange kit (Stratagene) and primers
GCCCTGCTACTGCTGGCCAAACTATCATATTTATCCTCC and GTTGGAGGATAAATATGA
TAGTTTGGCCAGCAGTAGCAGGGC. The second step was PCR amplification of the potentially
phosphorylated regions with 11 point mutations either inhibiting or mimicking phosphorylation from
minigenes ordered from IDT. The third step was blunt end ligation of the PCR products with the pSR-λ
N-HA-hPan3(PCD) linearized with MscI.
3.2.2. Cell culture and siRNA transfection.
Lifpofectamine RNAiMAX (Invitrogen) was used for consecutive reverse and forward siRNA
transfections of NIH3T3 B2A2 cells. For siRNA reverse transfection, 540 pmol SMARTpool Pan3
siRNA (Thermo Fisher Scientific), nonspecific siRNA (Thermo Fisher Scientific), or Stealth Pan2
siRNA (Duplex #1, Invitrogen) diluted with 3ml Opti-MEM serum-free medium (Invitrogen) was
mixed with 36ul of Lifpofectamine RNAiMAX (Invitrogen) in 10-cm dishes and incubated at room
temperature for 20 minutes. 2.4 x 106 NIH3T3 B2A2 cells re-suspended in 10ml medium containing
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130 ng/ml Tetrocycline were added to each of the 10-cm dishes containing siRNA-RNAiMAX
complexes, mixed well, and incubated at 37°C (5% CO2) for 24 hrs before changing fresh medium for
forward transfection. For the siRNA forward transfection, the siRNA-RNAiMAX complexes were
prepared in the same way as reverse transfection, added to the reverse transfected cells in 10-cm dishes,
and incubated at 37°C (5% CO2) for 24 hrs. The cells were then reseeded to new 10-cm dishes,
incubated at 37°C (5% CO2) for 24 hrs, and collected for Western blot analysis and poly(A) tail length
distribution profile analysis.
3.2.3. Analysis of poly(A) tail length distribution profiles.
Cytoplasmic RNA was extracted using RNeasy Mini kit (Qiagen) from cytoplasmic lysate of
transfected NIH3T3 B2A2 cells, during which the RNA was subject to on-column DNase digestion with
the RNase-free DNase set (QIAGEN). One µg of purified cytoplasmic RNA was incubated with 10 µCi
(5000 Ci/mmole) Cordycepin-5’ Triphosphate (PerkinElmer), 600 U Yeast poly(A) polymerase (Usb)
and 20 U Rnasin (Promega) in 1x poly(A) polymerase reaction buffer at 37 °C for 20 minutes. The 3’
end labeled RNA was then purified by phenol-chloroform extraction and ethanol precipitation. The
radioactivity of the product was assayed by liquid scintillation following TCA precipitation. A constant
amount of radioactivity (1000,000 cpm) was mixed and incubated with 20 µg yeast total RNA, 0.02 µg
RNase A (Roche), and 87 U RNase T1(Sigma-Aldrich) in a 20 µl reaction at 30 °C for 30 minutes to
digest RNA body (RNase A cleaves 3' of U and C residues and Rnase T1 cleaves after G residues). The
RNase digestion reaction was stopped by the addition of SDS and Proteinase K and incubation at 37 °C
for 30 minutes. The poly(A) RNA was phenol-chloroform extracted and ethanol precipitated. The
radioactivity of the product was assayed by TCA precipitation and liquid scintillation again. A constant
amount of radioactivity (15,000 cpm) was separated on an 8% denaturing polyacrylamide gel (with 7 M
urea). The gel was run at 300 V until the bromophenol blue dye was running out of the gel.
Autoradiography of the dried gel was performed at -80°C with an intensifying screen for 5.5 h.
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3.2.4. Cell culture and plasmid transfection.
NIH3T3 B2A2 cells were seeded to a density of 2.4 x 106/10-cm dish in 50 ng/ml tetracycline 24 hrs
before transfection. 40µl Lipofectamine 2000 (Invitrogen) and 1 ml Opti-MEM (Invitrogen) were mixed
and incubated at room temperature for 5 minutes. 13 µg total DNA were diluted into 1ml Opti-MEM,
mixed with the diluted Lipofectamine 2000, and incubated at room temperature for 25 minutes. The
mixture was then added to the cells in a 10-cm dish and incubated at 37°C in 5% CO2 for 18-20 hours.
For co-IP experiments, the transfected cells from each 10-cm dish were split to two 10-cm dishes and
incubated at 37°C in 8% CO2 for 24 hours before the cells were harvest. For immuno-fluorescence
staining experiments, the transfect cells were reseeded to glass chamber slides (BD Falcon) and
incubated at 37°C in 8% CO2 for 24 hours before the cells were fixed. For transcriptional pulse-chase
and Northern blot analysis, the transfected NIH3T3 B2A2 cells in each 10-cm dish were split to six 6cm dishes and one 35-mm dish and incubated at 37°C in 8% CO2 for 20 hours before the cells were
grown in tetracycline-free medium for 120 minutes to induce a transcriptional pulse driven by the Tetoff promoter of the reporter plasmid in transfected cells. At various time points after the transcription
pulse, cells from the 6-cm dishes were harvested and saved at -80C as pellets for isolating total RNA
and subsequent Northern blot analysis. Cells from the 35-mm dish were used for Western blot analysis.
3.2.5. Immunoprecipitation.
Cytoplasmic lysate was prepared by incubating harvested cells for 10 minutes on ice in 600ul of
lysis buffer (20 mM Tris-HCl pH 7.4 buffer, 150 mM NaCl, 1% NP-40, 1 mM Na orthovanadate, 1 mM
Na pyrophosphate, 1 mM NaF, and 1x protease inhibitor cocktail (Roche)) and spinning down nuclei
and cell debris at 400x g for 3 minutes at 4°C. 30 µl of the supernatant was saved as input at -80°C and
the rest of the supernatant was incubated with 30 µl of rat monoclonal anti-HA Affinity Matrix (Roche,
clone 3F10) in the presence of 90 µg/ml RNase A for 2 hours at 4°C. The beads were washed five times
with the lysis buffer and boiled in 30 µl of 2x SDS loading buffer for 5 minutes. The supernatant of the
boiled mixture was saved for Western blot analysis.
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3.2.6. Western blot analysis.
Either cytoplasmic or total cell lysate was used for Western, as indicated in each figure. Preparation
of cytoplasmic lysate was described in “Immunoprecipitation”. Total cell lysate was prepared by lysing
the cell pellets in SDS lysis buffer (60 mM Tris-HCl pH 6.8, 2% SDS, 1x protease inhibitor cocktail
(Roche), and 1 mM DTT) and filtering the lysate with a QIAshredder column (QIAGEN). Protein lysate
concentration was determined by Bio-Rad Dc protein assay (Bio-Rad). Except for the
immunoprecipitation experiment, 15 µg proteins were resolved on an 8% SDS-polyacrylamide gel and
transferred to a PVDF membrane. The PVDF blots were probed with different antibodies as described in
each figure. The following primary antibodies were used at indicated dilution: rabbit anti-Pan2 peptide
antibody at 1:2,000 (Bethyl), rabbit anti-Pan3 peptide antibody at 1:1,000 (Bethyl), mouse anti-tubulin
monoclonal antibody at 1:50,000 (Sigma-Aldrich), rat anti-HA monoclonal antibody at 1:3,000 (Roche),
mose anti-GAPDH monoclonal antibody at 1:50,000, and goat anti-Lamin B1 polyclonal antibody at
1:200 (Santa Cruz). After washing the membrane in 1xPBST buffer, the membrane was incubated with
HRP-conjugated donkey anti-rabbit IgG, goat anti-mouse IgG, or rabbit anti-goat IgG at 1:5,000 for 1
hour at room temperature. After washing in 1xPBST buffer again, the membrane was incubated with
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) for 5 minutes at room
temperature, and exposed to a SYNGENE Gnome gel documentation system (SYNGENE).
3.2.7. Northern blot analysis.
RNase H treatment of cytoplasmic mRNA after annealing to Oligo dT (Invitrogen) was performed
--

to generate poly(A) RNA. 10 µg of cytoplasmic RNA with or without RNase H treatment was
separated using 1.4% formaldehyde agarose gel electrophoresis, transferred to GeneScreen
Hybridization Transfer membrane (PerkinElmer), UV cross-linked to the membrane, and blotted with
32

P-labeled BBB or αGAPDH DNA probe dissolved in ULTRAhyb hybridization buffer (Ambion).

The 32P-labeled probes were prepared by labeling PCR amplified BBB and αGAPDH fragments with
α-[32P]dCTP (>6000 Ci/mmol; PerkinElmer) using the Rediprime II Random Prim Labeling System
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(GE Healthcare). The probes were purified using MicroSpin G-25 columns (GE Healthcare) before used
for hybridization.
3.2.8. Immunofluorescence microscopy.
This was conducted as described in Chapter 2. Briefly, transfected NIH3T3 cells were seeded to
chamber slides (BD Falcon) and cultured at 37°C (8% CO2) overnight before the cells were fixed. For
sodium arsenite (Sigma-Aldrich) or Leptomycin B (Sigma-Aldrich) treatment, cells were cultured in
medium containing 0.3mM sodium arsenite for 1 hour or 20 ng/ml Leptomycin B for 4 hours before the
cells were fixed. Ectopically expressed HA-tagged proteins were detected using rat anti-HA monoclonal
antibody (Roche, clone 3F10) and Alexa Fluor 350 goat anti-rat IgG (Invitrogen). Endogenous P bodies
were detected using rabbit anti-RCK/p54 (Bethyl) or human anti-GW182 (a gift from Dr. M.J. Fritzler,
University of Calgary, Canada) and Alexa Flour 555 goat anti-rabbit IgG (Invitrogen) or Alexa Flour
488 goat anti-human IgG (Invitrogen). Endogenous stress granules were detected using rabbit antiG3BP1 (a gift from Dr. R.Lloyd, Baylor College of Medicine, USA) and Alexa Flour 555 goat antirabbit IgG. All the primary and secondary antibodies used for immunofluorescence staining were
diluted at 1:1,000.
Images were obtained at RT by optical z-sectioning (20 sections in total, 0.2-μm-space between
sections) using an objective lens (100×/1.35 NA; Olympus) of a deconvolution microscope system
(DeltaVision) containing an inverted microscope (IX70; Olympus). Immersion oil (n = 1.514) was from
Applied Precision, LLC. Images were captured using a digital camera (Coolsnap HQ; Roper Scientific).
Stacks of 20 images were projected as a single 2D picture using softWoRx Explorer (version 3.3.6;
Applied Precision, LLC). The RGB colors of the resulting pictures were separated using Photoshop CS
(Adobe) (21).
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3.3. Results
3.3.1. siRNA-mediated knockdown of Pan3 or Pan2 in NIH 3T3 cells resulted in cytoplasmic
mRNAs with longer poly(A) tails

Although deletion of Pan3 and/or Pan2 in yeast extended poly(A) tail length of bulk mRNAs (30),
the effect of Pan3 or Pan2 depletion on the poly(A) tail of bulk mRNA in mammalian cells has never
been studied. Cytoplasmic mRNA from NIH 3T3 cells transfected with Pan3 or Pan2-specific or nonspecific siRNA was labeled at 3’ ends with 32P-Cordycepin (3’ deoxyadenosine) and treated with diluted
Rnase T1 and Rnase A to remove the non-poly(A) RNA body. The resultant poly(A) tails were resolved
on a denaturing urea-polyacrylamide gel to reveal poly(A) size distribution profile (Fig. 3.1 B). Poly(A)
tails of cytoplasmic mRNAs from Pan3 siRNA transfected cells were significantly longer than those
from non-specific siRNA transfected cells. Pan2 knockdown only slightly increased bulk mRNA poly(A)
tail length, probably because the knockdown of Pan2 was not complete (Fig. 3.1 A). This result
confirmed that Pan3 and Pan2 are general deadenylation factors in mammalian cells.
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Figure 3.1: Effects of Pan3 knockdown on ply(A) tails of bulk cytoplasmic mRNAs in NIH 3T3
Cells.
(A) Western Blot analysis of total cell lysate showing knockdown of Pan2 or Pan3 by siRNA.
(B)) Poly(A) tail length distribution profiles analyzed by denaturing urea
urea-polyacrylamide
polyacrylamide gel
electrophoresis. Following transfection with Pan3 siRNA or nonspecific si
siRNA
RNA or Pan2 siRNA,
cytoplasmic RNA was isolated from NIH 3T3 cells. The RNA samples were first labeled with 32P
labeled Cordycepin in the presence of yeast PAP, which are then digested with Rnase A and Rnase T1
to remove the RNA body. The resulting poly(A) or oligo(A) tails of RNA were resolved on a denaturing
urea-polyacrylamide gel. The bands running at ~70nt, 35nt, and 25nt can sometimes be observed in the
sample with NS siRNA treatment. (This siRNA knockdown experiment was repeated twice, while the
poly(A)
(A) profiling was repeated four times.)
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3.3.2. The N-terminal domain of Pan3 is dispensable for interaction with Pan2 in NIH 3T3 cells

Pan3 consists of a less conserved N-terminal domain, a pseudo kinase domain, and a conserved Cterminal domain (Fig. 3.2A). While the PAM2 motif in Pan3 N-terminal domain is responsible for
Pan3-PABP interaction (92), in yeast the C-terminal domain of Pan3p is responsible for interaction with
Pan2p (33). To map the Pan2-binding domains in human Pan3, I generated a series of HA-tagged Pan3
truncation mutants (Fig. 3.2 A) and tested their ability to pull down endogenous Pan2 in NIH 3T3 cell
lysate by co-IP (Fig. 3.2 B). The co-IP experiment showed that deletion of the N-terminal domain (1353) didn’t affect Pan3-Pan2 interaction and that deletion of the pseudo kinase domain (354-588)
significantly decreased the Pan3-Pan2 interaction, while deletion of the C-terminal domain (589-741)
abolished Pan3-Pan2 interaction. These results indicate that human Pan3 C-terminal domain is required
for interaction with Pan2 and that the pseudo-kinase domain enhances Pan2-Pan3 interaction. In
contrast, the N-terminal domain is dispensable for Pan3-Pan2 interaction.
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Figure 3.2: Only the C-terminal
C
domain of Pan3 is required for
interaction
ction with Pan2 in NIH 3T3
cells.
(A)) Schematic representation of wild
type Pan3 and Pan3 truncation mutants.
PAM2 motif is responsible for Pan3Pan3
PABP interaction.
(B)) Western blot analysis showing HAHA
tagged proteins and endogenous Pan2 in
cytoplasmic input
inpu (Upper two panels)
and in complexes precipitated by antianti
HA antibody conjugated to agarose
beads (Lower two panels). Mock
transfected cell lysate was used as a
negative control to show the specificity
of the precipitation. (The coIP
experiment was repeated
repeat once.)
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3.3.3. Domain requirement for tethered Pan3 to promote rapid deadenylation and decay of the
reporter mRNA

Pan3 interacts with both PABP and deadenylase Pan2 to recruit Pan2 to the mRNA poly(A) tail
associated with PABP (27, 33, 92, 93). To understand whether Pan3 simply recruits Pan2 or also
regulates Pan2 nuclease activity, λN-tagged Pan3 or Pan3 mutants were co-expressed with the reporter
mRNA BBB-4boxB and decay kinetics of the reporter mRNA in the cytoplasm of the NIH3T3 B2A2
cells were studied by Tet-off driven transcriptional pulse-chase experiments (Fig. 3.3 A) (81). The λN
tag, which is a 22 amino acid peptide derived from the N-terminus of the lambda bacteriophage N
protein, can specifically bind the boxB sequences in the 3’ untranslated region (UTR) of the reporter
mRNA (94).
As expected, tethering wild type Pan3 but not LacZ promoted deadenylation and decay of the
reporter mRNA in the cytoplasm (Fig. 3.3 C, D). In contrast, the stability of the cytoplasmic reporter
mRNA was not affected by tethering Pan3 mutants with deletion in N-terminal domain, pseudo kinase
domain, or C-terminal domain (Fig. 3.3.E-G). It is not surprising that tethering Pan3(1-588) did not
promote rapid deadenylation and decay of the reporter mRNA, since Pan3(1-588) cannot interact with
the deadenylase Pan2 (Fig. 3.3 F). However, both Pan3(288-741) and Pan3(1-353, 589-741), which
were able to interact with Pan2 (Fig. 3.2 B), also failed to stimulate reporter mRNA deadenylation and
decay when tethered (Fig. 3.3 E, G), suggesting that while Pan3 C-terminal domain is responsible for
recruiting Pan2, Pan3 N-terminal and pseudo kinase domains are also important for stimulating Pan2
deadenylase activity.
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Figure 3.3: Effects of tethered λN-HA-LacZ, λN-HA-Pan3, or λN-HA-Pan3
Pan3 truncation mutants
on the decay kinetics of the reporter mRNA BBB
BBB-4boxB.

(A)) NIH3T3 B2A2 cells were transiently transfected with a Tet promoter–regulated
regulated plasmid
encoding the reporter mRNA BBB
BBB-4boxB and the plasmids encoding λN-tagged
tagged proteins as
indicated. A plasmid encoding constitutively expressed alpha
alpha-globin–GAPDH
GAPDH mRNA was also
co-transfected
transfected to provide an internal standard for ttransfection
ransfection efficiency and sample handling.
(B)) Western blot analysis of total cell lysate showing expression levels of λN
N-tagged proteins
for the tethering experiment. Endogenous GAPDH was used as a loading control. (C-G)
(
Northern blots showing cytoplasmi
cytoplasmic decay of the BBB-4boxB
4boxB mRNA tethered with λN-HALacZ (C), λN-HA-Pan3(D),
), λN-HA-Pan3(288-741) (E), λN-HA-Pan3(1-588)
588) (F),
( λN-HAPan3(1-353, 589-741) (G).
). The times given at the top correspond to hours after tetracycline
addition. Poly(A)- RNA (A--) was prepared
pared in vitro by treating an RNA sample from an early
time point with oligo(dT) and RNase H. (This experiment was repeated once.)
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3.3.4. The N-terminal domain and pseudo kinase domain, but not the C-terminal domain, are
important for Pan3 to form many foci in NIH 3T3 cells

Pan3 not only co-localizes with P bodies but also is required for P-body formation in mammalian
cells (21). However, it was unclear which domains of Pan3 are important for its P body localization and
whether Pan3 is dependent on Pan2 for localizing to P bodies. To address these questions, the
aforementioned Pan3 truncation mutants were transiently expressed in NIH 3T3 cells and their subcellular localization were examined using indirect immuno-fluorescence microscopy (Fig. 3.4). AntiHA and anti-RCK/p54 antibodies were used to detect the HA-tagged Pan3 wt or mutants and
endogenous P bodies, respectively. Consistent with what we reported before, wild type Pan3 was mainly
cytoplasmic and forms many foci co-localizing with endogenous P bodies. Except the kinase domain
deletion mutant (Fig. 3.4 F), all other mutants showed increased nuclear distribution and were somewhat
able to localize to cytoplasmic P bodies. The expression level of HA-Pan3(354-741) was so low that I
did not find cells expressing HA-Pan3(354-741) under microscope. Interestingly, the Pan3 mutant with
most of the N-terminal domain deleted only formed a few foci (Fig. 3.4 C), while the Pan3 mutant with
C-terminal domain deleted still formed many foci (Fig. 3.4 D), suggesting that the N-terminal domain of
Pan3 is responsible for Pan3 colocalization with P-bodies in the cells. This experiment also indicated
that interaction with Pan2 is not required for Pan3 to enter P bodies, since the C-terminal domain
deletion mutant that no longer interacts with Pan2 could still co-localize with P bodies (Fig. 3.4 D, E).
Collectively, these results showed that both N-terminal and pseudo-kinase domains, but not C-terminal
domain, are necessary for Pan3 to colocalize with P bodies. Intriguingly, the N-terminal domain by
itself was sufficient to localize to P bodies.
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Figure 3.4: Indirect immunoimmuno
fluorescence staining showing
sub-cellular
sub
localization of
HA-tagged
HA
Pan3 or Pan3
truncation mutants and the P
body marker RCK/p54.

(A
A) Wild-type Pan3 formed
many cytoplasmic foci
colocalizing with P bodies.
(B
B) Pan3 could still localize
to most P bodies when half
of the Pan3 N-terminal
domain was deleted.
(C
C) Deletion of most of the
Pan3 N-terminal domain
impaired Pan3’s
P
ability to
form many cytoplasmic foci.
foci
(D)
( The Pan3 mutant with
C-terminal
C
domain deleted
was still able to form many
cytoplasmic foci.
foci
(E
E) Pan3 N-terminal domain
alone was able to colocalize
with P bodies.
(F
F) Deletion of the pseudo
kinase domain completely
abolished the ability of Pan3
to colocalize with P bodies.
(This experiment was repeated
twice.)
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3.3.5. Pan3 N-terminal domain may be phosphorylated to regulate Pan3 localization and/or
function

Since Pan3 N-terminal domain is important for Pan3 to stimulate Pan2 activity and to localize to P
bodies, I decided to take a close look at this domain. An alignment of Pan3 sequences from different
species revealed that the N-terminal domain is less conserved than the other domains (Fig. 3.5 A).
However, the N-terminal domains of all the analyzed Pan3 sequences are proline-rich. Since the
conformation of proline is rigid, proline-rich motifs often tend to form disordered regions that are
difficult to characterize by NMR spectroscopy or X-ray diffraction (95). Indeed, the N-terminal domains
of both human and yeast Pan3 are predicted to be intrinsically disordered by the VL-XT software(96).
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terminal domain contains a conserved proline
proline-rich,
rich, disordered region.
Figure 3.5: Human Pan3 N-terminal
(A)) Alignment of Pan3 protein sequences from yeast, xenopus, mouse and human using ClustalW2.
Proline residues are highlighted in yellow. ((B-C)) Prediction of intrinsically disordered region in human
Pan3 (B) and yeast Pan3 (C)) using VL
VL-XT
XT from PONDR. Regions with a ponder score above 0.5 are
considered to be disordered by the VL
VL-XT.
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Both proline-rich motifs and intrinsically disordered regions are often target sites for
phosphorylation and are involved in protein-protein interaction (95, 97). HA-tagged wild-type Pan3 and
Pan3 N-terminal domain appeared as double bands on the Western blot membrane and the upper band
was sensitive to calf intestinal alkaline phosphotase (CIAP) treatment (Fig. 3.6 A), suggesting that Pan3
N-terminal domain indeed can be phosphorylated in NIH 3T3 cells.
Two different online tools were used to predict phosphorylated residues in Pan3 N-terminal domain.
The first tool is DEEP (Disorder Enhanced Phosphorylation Predictor), which predicts phosphorylation
sites based on both disorder information and position-specific amino acid frequencies (98). The second
tool, ScanSite 2.0, can identify short protein sequence motifs that are substrates for protein Ser/Thr- or
Tyr-kinases (99). Although the two tools use different methods to predict protein phosphorylation sites,
they both predicted that a small region around a.a. residue 200 in Pan3 N-terminal domain is likely
hyperphosphorylated (Fig. 3.6 B, C).
To study the functional significance of Pan3 N-terminal domain phosphorylation, eleven predicted
phosphorylation sites around residue 200 in λN-HA-tagged Pan3 were mutated to either inhibit or
mimic phosphorylation at those sites. The sequences of part of the N-terminal domain of wild type Pan3,
Pan3 mutant nonphosphorylatable at the eleven sites(NP11), and phosphor-mimetic Pan3 mutant (PM11)
were aligned, with the mutated residues highlighted in white background (Fig. 3.6 D). Western blot
analysis showed that both λN-HA-tagged Pan3(PM11) and λN-HA-tagged Pan3(NP11) were
expressed in NIH 3T3 cells after transient transfection (Fig. 3.6 E).
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Figure 3.6: Mutagenesis to mimic or inhibit phosphorylation in the disordered region of Pan3.
(A) Western blot analysis of HA
HA-tagged wild-type Pan3 (Left panel) or HA-tagged
tagged Pan3 N-terminal
N
domain (Right panel) in CIAP treated or mock treated cell lysate. (CIAP treatment of wild-type
wild
Pan3
was repeated once; CIAP treatment of Pan3(1
Pan3(1-353) was performed only once.)(B)) Prediction of Pan3
phosphorylation sites using PONDR. ((C) Prediction of Pan3 phosphorylation
ylation sites using ScanSite. (D)
(
Local sequence alignment of wild
wild-type
type Pan3, Pan3(NP11), and Pan3(PM11) using ClustalW2. The
eleven residues with white background are mutated to either mimic phosphorylation (PM11) or inhibit
phosphorylation (NP11). (E)) We
Western
stern blot analysis of total cell lysate showing the expression of λNHA-tagged
tagged wild type Pan3, Pan3(NP11), and Pan3(PM11).
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Interestingly, mutations at the eleven potential phosphorylation sites in Pan3 N-terminal domain
dramatically changed Pan3 localization. While λN-HA-tagged Pan3 mostly formed cytoplasmic foci
co-localizing with P bodies (Fig. 3.7 A), λN-HA-tagged Pan3(NP11) mimicking hypo-phosphorylation
in Pan3 N-terminal domain induced formation of large, irregularly shaped speckles co-localizing with P
bodies (Fig. 3.7 B). On the other hand, λN-HA-tagged Pan3(PM11) mimicking hyper-phosphorylation
in Pan3 N-terminal domain induced formation of nuclear foci (Fig. 3.7 C), similar to the localization of
HA-tagged Pan3(1-353) (Fig. 3.4 E). Moreover, λN-HA-tagged Pan3(PM11) in the cytoplasm no
longer enriches in P bodies (Fig. 3.7 C).
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Figure 3.7 Mutations at the potential phosphorylation sites in Pan3 N-terminal
terminal domain
dramatically changed Pan3 localization.
Immuno-fluorescence
fluorescence staining showing the localization of the P body marker RCK/p54 and λN-HAtagged wild type Pan3 (A),
), Pan3(NP11) ((B), or Pan3(PM11) (C). (This experiment was repeated
repeat twice.)
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The λN-HA-tagged Pan3(PM11) nuclear foci resemble the nuclear HA-tagged Pan3 foci formed
upon leptomycin B (LMB) treatment, which inhibits CRM1-mediated nuclear export (100) (Fig. 3.8 A).
Interestingly, LMB treatment also increased the relative intensity of the upper band of HA-Pan3 (Fig.
3.8 B). It is possible that LMB treatment resulted in both Pan3 nuclear localization and hyperphosphorylation.
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Figure 3.8: Effects
fects of Leptomycin B treatment on HA
HA-tagged Pan3.
fluorescence staining showing the localization of HA
HA-tagged
tagged Pan3 upon Leptomycin
(A) Immuno-fluorescence
treatment. (B) Western blot analysis of total cell lysate showing that Leptomycin B (LMB) treatment
may affect phosphorylation of HA
HA-tagged Pan3. (This experiment was performed once.)
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The observation that sub-cellular localizations of λN-HA-tagged Pan3(PM11) and Pan3(NP11) are
distinct from that of λN-HA-tagged Pan3 suggests that these mutants may have effects different from
Pan3 on mRNA decay kinetics. To test this possibility, Pan3(PM11) or Pan3(NP11) was tethered to the
3’UTR of the reporter pTet-BBB-4boxB through specific λN-boxB interaction, followed by Tet-off
driven transcriptional pulse-chase experiments for studying reporter mRNA decay kinetics. The results
showed that tethering either one of Pan3, Pan3(PM11), or Pan3(NP11) promoted cytoplasmic
deadenylation and decay of the reporter mRNA BBB-4boxB (Fig. 3.9). These results strongly suggest
that phosphorylation status of the eleven residues in Pan3 N-terminal domain does not directly affect
Pan3’s ability to promote rapid deadenylation and decay. Instead, it affects Pan3 subcellular
localization.
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Figure
igure 3.9: Effects of tethered Pan3(PM11) or Pan3(NP11) on reporter mRNA decay.

(A)) Western blot analysis of total cell lysate showing expression of λN-HA-tagged
tagged proteins for the
tethering experiment. (B-D)) Northern blots showing cytoplasmic decay of the BBB-4boxB
BBB
mRNA
tethered with λN-HA-Pan3 (B
B), λN-HA-Pan3(PM11) (C), and λN-HA-Pan3(NP11)
Pan3(NP11) (D). A plasmid
encoding constitutively expressed alpha
alpha-globin–GAPDH mRNA was also co-transfected
transfected to provide an
internal standard for transfection efficiency and sample handling. The times given at the top correspond
corr
to hours after tetracycline addition. Poly(A)
Poly(A)- RNA (A-)) was prepared in vitro by treating an RNA
sample from an early time point with oligo(dT) and RNase H. (This experiment was performed once.)
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3.4. Discussion

In this study, I showed that siRNA-mediated knockdown of Pan3 resulted in bulk cytoplasmic
mRNAs with longer poly(A) tails in NIH 3T3 cells(Fig. 3.1). Pan2 knockdown had a similar but
weaker effect, probably because the knockdown was not complete (Fig 3.1). This phenotype is
reminiscent of that observed in budding yeast, where Pan3p-Pan2p was reported to trim the poly(A) tails
of newly synthesized transcripts to message-specific length [35], although it was unclear whether this
trimming occured in the nucleus or in the cytoplasm. Interestingly, my preliminary data showed that
HA-tagged wild-type Pan3 formed nuclear foci when the cells were treated with leptomycin B (Fig. 3.8).
This observation is consistent with a speculation that the Pan3-Pan2 complex may trim the poly(A) tails
of nascent transcripts at the transcription sites.
A novel role for Pan3 in regulating Pan2 poly(A) nuclease activity is also suggested by my domain
dissection study on Pan3. Tethering wild-type Pan3, but not the Pan3 mutant deficient in Pan2
interaction, promoted deadenylation and degradation of the reporter mRNAs in NIH 3T3 cells (Fig. 3.2
& Fig. 3.3 F), suggesting that interaction with Pan2 is important for Pan3 to promote deadenylation.
Interestingly, tethering Pan3 mutant that lacks N-terminal domain or pseudo-kinase domain but is
capable of interacting with Pan2 also did not elicit rapid deadenylation and decay of the reporter mRNA
(Fig. 3.2 & Fig. 3.3 E&G). These results suggest that the N-terminal and pseudo-kinase domains are
also required for Pan3 to promote the poly(A) nuclease activity of Pan2. Since purified human Pan2
alone can trim oligo(A) in the absence of PABP in an in vitro reaction albeit slowly [27], it is possible
that the N-terminal domain and the pseudo kinase domain of Pan3 are required to release PABP at the
very 3' end of the poly(A) tail, making the poly(A) tail more accessible to Pan2. Consistent with this
idea, the Pan3 N-terminal domain indeed contains a PAM2 motif for interaction with PABP [92].
Previously, we have shown that deadenylation is required for mRNAs to enter or form P bodies in
mammalian cells and that both Pan3 and Pan2 are enriched in P bodies [21]. Therefore, the Pan3-Pan2
complex may be recruited to P bodies via aggregation of mRNPs that contain mRNAs whose poly(A)
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tails just have been shortened by the Pan3-Pan2 complex. However, my experiments showed that
localization of Pan3 to P-bodies is independent from its ability to interact with Pan2 or promote
deadenylation (Fig 3.4). Moreover, my observation that siRNA-mediated knockdown of Pan3, but not
Pan2, inhibited P body formation in NIH 3T3 cells (Fig. 2.3 &2.4) suggests that Pan3 plays an active
role in P body formation. Collectively, my data indicate that in addition to playing a regulatory role in
deadenylation, Pan3 also contributes to P body formation by exerting some kind of Pan2-independent
function.
My data also suggest that the localization and functions of Pan3 are likely regulated by
phosphorylation of a disordered region in Pan3 N-terminal domain. The proline-rich human Pan3 Nterminal domain is predicted to contain an intrinsically disordered region by PONDR. Interestingly,
yeast Pan3p also contains an N-terminal disordered region (Fig. 3.5), suggesting that the disordered
region may be functionally important. As intrinsically disordered regions are frequently phosphorylated
to regulate protein functions, I also searched the kinase target sequences in the intrinsically disordered
region of Pan3 N-terminal domain by Scansite (Fig. 3.6). Phosphotase treatment greatly reduced the
relative intensity of the upper band of HA-Pan3 and HA-Pan3 N-terminal domain doublet on Western
blot membranes (Fig. 3.5 & 3.6), suggesting that the Pan3 N-terminal domain can be phosphrylated.
Mutations (NP11) that inhibit phosphorylation at eleven potential phosphorylation sites in Pan3 Nterminal domain induced formation of abnormally large P bodies (Fig. 3.7). The increase of P body size
is unlikely caused by inhibition of mRNA decay within the aberrant P bodies, as tethered Pan3(NP11)
can still interact with Pan2 and promote decay of the reporter mRNA (Fig. 3.9). Therefore, it is possible
that phosphorylation of some of these residues may be required for Pan3 in P bodies to be released back
to the cytosol. On the other hand, Pan3(PM11), which contains mutations that mimic phosphorylation at
the eleven potential phosphorylation sites, is diffused in the cytoplasm, but highly enriched in nuclear
foci (Fig. 3.7). Although the distinct localization phenotypes of Pan3(NP11) and Pan3(PM11) might
stem from structural defects caused by the mutations, it is also possible that phosphorylation states of
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Pan3 N-terminal domain may determine the localization and function of Pan3. It will be important to
confirm that endogenous Pan3 N-terminal domain indeed is hyper-phosphorylated.
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Chapter 4: Bioinformatic Analysis of
Human mRNA Processing Body
Components
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4.1. Introduction

mRNA processing bodies (P bodies) are dynamic cytoplasmic foci containing non-translating
messenger ribonucleoproteins (mRNPs) as well as proteins for translational inhibition and mRNA
degradation. Conserved from yeast to human, P bodies have a diameter of 100-300 nm (65). These
membrane-free structures are mainly anchored to microtubules while constantly moving around in the
cytoplasm (66). Fluorescence microscopy studies revealed that P bodies contain translationally inhibited
mRNAs and many proteins involved in translational inhibition and mRNA degradation (68). In contrast,
most factors involved in mRNA translation, for example eIF4G and ribosome subunits, are normally
absent from P bodies (71).
P bodies provide another potential layer of post-transcriptional gene regulation because mRNAs in P
bodies can be translationally inhibited and either degraded or released for translation. Since P bodies are
ribosome-free, mRNAs in P bodies cannot be translated. mRNAs in P bodies can be degraded, as
inhibition of 5’ to 3’ decay by knocking down Xrn1 increased P body sizes and mRNA decay
intermediates were found in P bodies (72). However, P bodies may also be temporary storage sites for
some mRNAs before they are degraded, as suggested by an observation that a P body mRNA encoding
cationic amino acid transporter 1 (CAT-1) was released from P bodies and subsequently translated when
the cells were subjected to different stresses (73). Therefore, P bodies may function as a “recycle bin”
where the fates of arrested non-translating mRNAs (either degradation or release) will be determined.
Although over 250 papers on P bodies or P body components in different species have been
published, the biological role and physiological significance of P-bodies remain unclear. Currently, a
comprehensive list of reported P body components is not available, and our ability to study P body
components as a whole is limited. For example, how many P body proteins have been found? How can
they be classified based on their known functions? How do they interact with each other and other
cellular proteins? Answers to these questions are likely to provide key insight into the biological
functions of P bodies and thus regulation of P body dynamics.
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In this study, a list of P body proteins in different species reported to date is provided. Reported and
predicted human P body proteins are then grouped based on their functions. Protein-protein interaction
analysis reveals that many P body proteins form complex interaction networks with each other as well
as other cellular proteins that have not been reported as P body components yet. Interestingly, some of
these cellular proteins can interact with three or even more P body components, suggesting that these
proteins may also localize to P bodies or be important for P body dynamics and functions.

4.2. Methods and Results

4.2.1. Currently reported P body protein components in different species
In order to have a comprehensive view of known P body proteins, over 250 Pubmed articles
published since 2002 that contain various synonyms of P bodies in their titles or abstracts were
identified. After careful examination of immunofluorescence microscopic evidence for P-body
localization in each article, a list of currently reported P body protein components in different species
was generated (Table. 4.1). Together, 57 human proteins, 10 mouse proteins, 30 yeast proteins, and 17
proteins from plants, worms, or fruit fly were included in the list.
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Species
Arabidopsis
Arabidopsis
Arabidopsis
C. elegans
C. elegans
C. elegans
C. elegans
C. elegans
Drosophila
Drosophila
Drosophila
Drosophila
Drosophila

Gene_ID
837357
831201
820530
181719
181504
175680
175654
174808
36544
33934
39957
37528
43808

Uniprot_Ac
Q9SJF3
Q8GW31
Q9LTT8
Q17740
Q20578
Q21992
Q19818
Q20374
Q32KD4
Q9VMA3
Q9VVI2
Q9NFU0
Q8SY33

Name
DCP1
DCP2
VCS
AIN-1
ALG-1
LARP-1
NHL-2
PATR-1
AGO1
Cup
EDC3
FMRP
GW182

Drosophila
Drosophila
Drosophila

34364
32926
37065

P23128
Q9V3F9
P25159

Me31B
Out
Staufen

Drosophila
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human

39430
26523
27161
192669
192670
200316
60489
29883
57472
64506
55802
196513
167227
80153
1977
56478
10922

Q9VTZ0
Q9UL18
Q9UKV8
Q9H9G7
Q9HCK5
Q8IUX4
Q9HC16
Q9UIV1
Q9ULM6
Q9BZB8
Q9NPI6
Q8IZD4
Q8IU60
Q96F86
P06730
Q9NRA8
Q14296

Tral
Ago1
Ago2
Ago3
Ago4
APOBEC3F
APOBEC3G
Caf1
Ccr4
CPEB1
Dcp1a
Dcp1b
Dcp2
Edc3
eIF4E
eIF4E-T
FAST

Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human

23644
25929
220988
3064
10526
79727
27257
57819
27258
25804
23658
11157
51690
92312
84206
4343

Q6P2E9
Q8TEQ6
P51991
P42858
O15397
Q9H9Z2
O15116
Q9Y333
P62310
Q9Y4Z0
Q9Y4Y9
P62312
Q9UK45
A1L020
Q6ZN04
Q9HCE1

Ge-1
Gemin5
hnRNP A3
Htt
Imp8
Lin28
LSm1
LSm2
LSm3
LSm4
LSm5
LSm6
LSm7
Mex-3A
Mex-3B
MOV10

Alias

EDC4, GE-1
GW182

Pat1

Gawky
Dhh1,
RCK/P54

RAP55,
LSM14A
EIF2C1
EIF2C2
EIF2C3
EIF2C4

CNOT7
CNOT6

LSM16
EIF4ENIF1
FASTK
EDC4,
HEDLS

IPO8
ZCCHC1

Reference
(101)
(101)
(101)
(102)
(102)
(103)
(104)
(105)
(106)
(107)
(108)
(109)
(106)
(110)
(107)
(109)
(108)
(111)
(111)
(112)
(113)
(114)
(114)
(21)
(76)
(115)
(71)
(76)
(116)
(117)
(74)
(74)
(71)
(118)
(119)
(120)
(121)
(122)
(123)
(124)
(124)
(124)
(124)
(124)
(124)
(124)
(125)
(125)
(126)
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Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast

340152
9924
255967
219988
5093
5094
5610
55629
26065
1656
6737
23381
23293
9887
27327
23112
57690
10766
3842
7538
5976
65110
65109
54464
4904
15572
232943
83557
636931
378430
244551
170722
22695
317755

545824
854016
855605
854344
854379
851394
851787
856700
853318
854504
850455
851389
854773
856799
850440
852391
855788
850647
852513

A2A288
Q504Q3
Q58A45
Q86TB9
Q15365
Q15366
P19525
Q9NPJ4
Q8ND56
P26196
P19474
Q9UPR3
Q86US8
Q92540
Q8NDV7
Q9UPQ9
Q9HCJ0
Q14106
Q92973
P26651
Q92900
Q9H1J1
Q9BZI7
Q8IZH2
P67809
Q61701
Q91W40
Q8K3Y3
Q1PSW8
P60322
P60324
Q80SZ6
P22893
Q80SU3
C3VD30
Q12517
P53550
Q12123
P06634
P39517
Q03466
P39998
P47017
P19524
P25655
P06100
P06102
P34909
P25644
P38254
P39008
Q07807
P32831

P58(TFL)
Pan2
Pan3
PatL1
PCBP1
PCBP2
PKR
PNRC2
RAP55
RCK/p54
Ro52
SMG5
SMG6
SMG7
TNRC6A
TNRC6B
TNRC6C
Tob2
TNPO1
TTP
UPF1
UPF3a
UPF3b
Xrn1
YB-1
HuD
KLC3
Lin28
mLin41
Nanos2
Nanos3
NXF7
TTP
Zar1
Zar1L
Dcp1p
Dcp2p
Dcs2
Ded1p
Dhh1p
Ebs1p
Edc3p
Lsm1p
Myo2p
Not1p
Not2p
Not3p
Not4p
Pat1p
Pby1p
Pop2p
Puf3p
Rbp1p

USP52

HNRPE1
HNRPE2

LSM14A
DDX6
SSA1

GW182

TRN
Tis11, Zfp36

YBX1
Elavl4

Tis11, Zfp36

LSM16

Ngr1p

(127)
(21)
(21)
(128)
(129)
(130)
(131)
(132)
(133)
(75)
(134)
(135)
(70)
(135)
(136)
(136)
(137)
(49)
(138)
(138)
(135)
(70)
(70)
(124)
(139)
(140)
(141)
(123)
(142)
(143)
(144)
(120)
(71)
(67)
(67)
(72)
(72)
(145)
(146)
(72)
(147)
(148)
(72)
(149)
(150)
(150)
(150)
(150)
(72)
(151)
(77)
(152)
(153)
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Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast
Yeast

853301
852013
854883
856351
855898
853688
854889
855104
856476
852963
854541
852702

P20433
P34087
Q02773
P10080
P06245
P05986
P09733
P30771
P38798
P48412
Q08831
P22147

Rpb4p
Rpb7p
Rpm2p
Sbp1p
Tpk2
Tpk3
Tub1
Upf1p
Upf2p
Upf3p
Vts1p
Xrn1p

Kem1p

(154)
(155)
(156)
(157)
(158)
(158)
(151)
(69)
(69)
(69)
(159)
(72)

Table 4.1 A comprehensive list of reported P body components in different species. The list was
manually generated based on published research articles in Pubmed. NCBI Gene IDs and Uniprot
Accession Numbers are provided for the convenience of future bioinformatic analysis.
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4.2.2. Functional categorization of reported and predicted human P body components

Most of the P body components are conserved across species, but the localization of some of the P
body proteins was only studied in non-human species. Since the functions and localizations of many P
body components are conserved across eukaryotes, we assume that human orthologs of P body proteins
found in other species will also localize to human P bodies. The NCBI HomoloGene database was
searched and 22 potential human P body components whose orthologs have been reported to localize to
P bodies in other species were identified (Table 4.2, italic rows). To better understand the functions of
human P body components, the reported and predicted human P body proteins were clustered based on
their known functions (Table 4.2).
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Gene Name

Homolog in
PBs
ARE-mediated mRNA degradation
TNPO1
TRN

TTP

Alias

ZFP36

Nonsense-mediated decay
PNRC2
SMG5
SMG6

EST1B
EST1A

SMG7

EST1C

UPF1
UPF2

Yeast Upf2p

UPF3A
UPF3B

Gene silencing by miRNA or siRNA
EIF2C1
AGO1

Function(s)

Reference

Nuclear transport receptor; trafficking of TTP
between the PBs and SGs and modulates AREcontaining mRNA stability.

(138, 160)

Binds to and destabilize some mRNAs with AUrich elements

(161, 162)

A bridge between the mRNA decapping complex
and the NMD machinery
Required for the dephosphorylation of UPF1
Required for the dephosphorylation of UPF1.
Telomere maintenance
Binds to phosphorylated UPF1; Triggers mRNA
decay
Binds to eRF1 and eRF3; Required for nonsensemediated mRNA decay
Bridges Upf1 to the exon junction complex during
nonsense-mediated mRNA decay; Stimulate
helicase activity of Upf1
Less effective than Upf3b to induce nonsensemediated mRNA decay
Bridges Upf1 to the exon junction complex during
nonsense-mediated mRNA decay; Stimulate
helicase activity of Upf1; Required for the
phosphorylation of UPF1

(132)

mi/siRNA mediated mRNA decay and
translational repression
mi/siRNA mediated mRNA decay and
translational repression

(170)

(135, 163)
(70, 164, 165)
(135, 166)
(135, 167)
(69, 168)

(70, 169)
(70, 167, 168)

EIF2C2

AGO2

EIF2C3

AGO3

mi/siRNA mediated mRNA decay and
translational repression

(112, 170)

EIF2C4

AGO4

mi/siRNA mediated mRNA decay and
translational repression

(113, 170)

Contributes to RNA-mediated gene silencing
through association with Argonaute and P bodies
Nuclear import; Function in cytoplasmic miRNAguided gene silencing and affects nuclear
localization of Ago proteins
Interacts with Ago1 and Ago2; Required for
siRNA-mediated mRNA cleavage
Recruited by Agonaute proteins, important for
miRNA-mediated deadenylation and translational
repression
Recruited by Agonaute proteins, important for
miRNA-mediated deadenylation and translational
repression
Recruited by Agonaute proteins, important for
miRNA-mediated deadenylation and translational
repression
Interacts with Ago1 and Ago2; Participates in
RNA silencing

(121)

HTT
IPO8

Imp8

MOV10
TNRC6A

GW182

TNRC6B

TNRC6C

UPF1
Negative regulation of miRNA pathway
LIN28
LIN41

TRIM71

Mouse Lin41

Inhibits let-7 miRNA maturation; An RNA binding
protein in PBs and SGs.
A stem cell specific E3 ubiquitin ligase for the
miRNA pathway protein Ago2.

(170, 171)

(122, 172)

(126)
(173, 174)

(113, 136)

(19, 113)

(175)

(123, 176, 177)
(142)
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Binding to telomere or telomerase
hnRNPA3
MOV10
PCBP2

HNRPE2

SMG6

EST1A

Transcription
CNOT1-4

Yeast Not1-4p

PCBP1

HNRPE1

POLR2G
YB-1

RPB7
YBX1

Splicing
PCBP1

HNRPE1

YB-1

YBX1

mRNA trafficking
FMR1
FMRP

Yeast Rpb4p

Drosophila
FMR1

hnRNPA3
KLC3
MYO5C
NXF2

Mouse KLC3
Yeast Myo2p
Mouse NXF7

STAU1

Drosophila
Staufen

TUBA1C
mRNA stabilization
EIF4E

Yeast Tub1p

HUD

ELAVL4

Mouse HuD

PCBP1

HNRPE1

PCBP2

HNRPE2

Translation inhibition or activation
CPEB1
DDX6
EIF2C2

RCK/p54
AGO2

EIF4E
EIF4ENIF1

GEMIN5
PatL1

EIF4T

Binding to the telomeric sequence; Cytoplasmic
trafficking of RNA.
Inhibits production of infectious retroviruses when
over expressed; Binds to telomere.
Interacts with telomeric DNA and telomerase
RNA; mRNA stabilization and destabilization
Required for the dephosphorylation of UPF1.
Telomere maintenance

(120, 178, 179)
(180, 181)
(182-184)
(70, 164, 165)

Form complexes with the deadenylases CNOT6
and CNOT7orCNOT8; Involved in mRNA splicing,
transport, and deadenylation.
Transcription activation; Splicing; mRNA
stabilization; cap-dependent mRNA translational
inhibition; IRES-driven translation activation
The seventh largest subunit of RNA polymerase II
Transcription activation; Splicing enhancement;
Translation activation by binding to 5’-UTR

(37, 185)

Transcription activation; Splicing; mRNA
stabilization; cap-dependent mRNA translational
inhibition; IRES-driven translation activation
Transcription activation; Splicing enhancement;
Translation activation by binding to 5’-UTR

(171, 186, 187)

Involved in translation regulation and trafficking
of certain mRNA.
Binding to the telomeric sequence; Cytoplasmic
trafficking of RNA.
May bind cargo and regulate kinesin activity.
Granule trafficking
Nuclear RNA export; Cytoplasmic mRNA
localization
mRNA localization and translation regulation;
Competes with Upf2 to interact with Upf1 to
promote mRNA decay.
Tubulin alpha-1C chain

(109, 191, 192)

Binds mRNA 5' cap to stabilize mRNA and
promote translation initiation
Binds to and stabilize some AU-rich element (ARE)
containing mRNAs
Transcription activation; Splicing; mRNA
stabilization; cap-dependent mRNA translational
inhibition; IRES-driven translation activation
Interacts with telomeric DNA and telomerase
RNA; mRNA stabilization and destabilization

(197)

During the early development, it behaves first as
an inhibitor and later as an activator of translation.
Required for microRNA-induced gene silencing
Competes with eIF4E to bind to the 5' cap to
inhibit translation
Binds mRNA 5' cap to stabilize mRNA and
promote translation initiation
Mediates the nuclear import of EIF4E. Interacts
with the cap binding protein 4E to inhibit
translaiton.
Inhibits both cap-dependent and IRES-driven
translation initiations
May be a decapping activator and translation

(171, 186, 187)

(154)
(188-190)

(188-190)

(120, 178, 179)
(141)
(149, 193)
(120, 194)
(109, 195, 196)

(151)

(198-200)
(171, 186, 187)

(182-184)

(115)
(75)
(201)
(197)
(74, 202)

(203)
(128)
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PCBP1

HNRPE1

RAP55
YB-1

TRAL
YBX1

Deadenylation
CNOT1-4

repressor
Transcription activation; Splicing; mRNA
stabilization; cap-dependent mRNA translational
inhibition; IRES-driven translation activation
Translation inhibition
Transcription activation; Splicing enhancement;
Translation activation by binding to 5’-UTR
Yeast Not1-4p

CNOT6

Ccr4

CNOT7

Caf1

NANOS2

Mouse Nanos2

PAN3
PAN2
TOB2
Decapping
DCP1A
DCP1B
DCP2
EDC3

GE-1

Hedls, EDC4

LSM1-7
PATL1
5' to 3' Exonuclease activity
XRN1
Helicase activity
DDX3Y
Yeast Ded1p
DDX6
RCK/p54
MOV10

UPF1
Endonuclease activity
EIF2C2
Ago2

FAST

PRKACB

FASTK

Yeast Tpk2p

(204)
(188)

Form complexes with the deadenylases CNOT6
and CNOT7orCNOT8; Involved in mRNA splicing,
transport, and deadenylation.
Deadenylase required for second phase of
deadenylation
Deadenylase required for second phase of
deadenylation
Recruits Ccr4-NOT deadenylation complex to
mRNAs
Interacts with both PABP and the deadenylase
Pan2 to stimulate Pan2 activity
Deadenylase required for first phase of
deadenylation
Interacts with PABP and recruit the deadenylase
Caf1

(37)

Decapping enzyme subunit
Decapping enzyme subunit
Catalytic subunit of decapping enzyme
Interact with multiple components of the
decapping machinery, including DCP1, DCP2, and
DDX6
Promotes complex formation between DCP1A and
DCP2. Enhances the catalytic activity of DCP2
Sm-like protein complex, decapping activator
May function as a decapping activator and
translation repressor

(71)
(76)
(76, 116)
(205-207)

5' to 3' riboexonuclease

(124, 208)

Probable ATP-dependent RNA helicase.
Helicase activity is required for translational
inhibition and P body formation.
Probable RNA helicase; interacts with Ago1 and
Ago2; Required for siRNA-mediated mRNA
cleavage
Helicase activity is required to promote mRNA
decay.

(146)
(209)

Cleaves both passenger strand and mRNA targets
of siRNAs
Functions in nonsense-mediated decay
Probable endonuclease

SMG6
ZC3H12D
P58(TFL)
Protein kinase activity
EIF2AK2
PKR

(171, 186, 187)

Phosphorylates eIF2alpha to inhibit translation in
virus infected cells; Targeted to PBs by the E6
oncoprotein of HPV
In response to Fas receptor ligation, it
phosphorylates TIA1, an apoptosis-promoting
nuclear RNA-binding protein.
Mediates cAMP-dependent signaling triggered by
receptor binding to GPCRs.

(19, 21, 76)
(21)
(143)
(27, 92)
(16, 21)
(49)

(118, 205)
(88, 124)
(128)

(126)

(210, 211)

(212, 213)
(214, 215)

(131, 216)

(217)

(218)
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PRKX

Yeast Tpk3p

A serine threonine protein kinase that has
similarity to the catalytic subunit of cyclic AMP
dependent protein kinases.

(219)

Ubiquitin ligase activity
LIN41
TRIM71

Mouse Lin41

A stem cell specific E3 ubiquitin ligase for the
miRNA pathway protein Ago2
E3 ubiquitin ligase; interacts with Dcp2 to enhance
its decapping activity

(142)

Compete with eIF4E to bind to the 5' cap to inhibit
mRNA translation.
Binds mRNA 5' cap to stabilize mRNA and
promote translation initiation
Binds to m7G cap of mRNAs

(201)

TRIM21

Ro52

Cap-binding activity
EIF2C2
AGO2
EIF4E
GEMIN5
Response to virus
APOBEC3F
APOBEC3G
EIF2AK2

PKR

MOV10
Miscellaneous
LARP1

C. elegans
LARP-1

MEX-3A
MEX-3B
NANOS3
ZAR1
ZAR1L

Mouse Nanos3
Mouse ZAR1
Mouse ZAR1L

(134, 220)

(197)
(221)

A cytidine deaminase that restricts retroviral
replication
A cytidine deaminase that restricts retroviral
replication
Double-stranded RNA protein kinase targeted to
PBs by the E6 oncoprotein of HPV
Inhibits production of infectious retroviruses when
over expressed; Binds to telomere.

(222)

RNA binding

(223)

RNA binding protein; May be involved in posttranscriptional regulatory mechanisms.
RNA binding protein; May be involved in posttranscriptional regulatory mechanisms.
Germ cell-specific RNA binding protein
Zygote arrest protein 1
ZAR1-like protein

(125)

(222)
(131, 216)
(126, 180, 181)

(125, 224)
(225)
(67)
(67)

Table 4.2: Functional categorization of reported and predicted human P body components.
P body proteins predicted based on homology are in italic. Some P body proteins with diverse functions
are listed in different groups.
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4.2.3. Protein-protein interactions among P body components

Proteins often exert their functions through interactions with other protein molecules. To understand
how different P body components aggregate to form microscopically visible foci and how P body
components are functionally linked, protein-protein interactions (PPIs) among P body components
themselves were analyzed. To this end, 79 gene names of reported and predicted human P body
components were submitted to the STRING database version 8.2 to retrieve 90 PPIs among human P
body proteins detected by anti-tag coimmunoprecipitation (coIP), yeast two-hybrid, and pulldown
experiments. (226). Another 32 PPIs were identified by manually checking recent publications about P
body components. The 122 PPIs among 55 of the 79 reported and predicted P body components were
then visualized using Cytoscape version 2.6.3 (227). Proteins with similar or related functions are
represented with similarly colored nodes, and interactions among the proteins were denoted by lines
(Fig. 4.1). It should be noted that the interactions detected by coIP experiments are not necessarily direct.
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Figure 4.1: Protein-protein interactions among P body components. 120 PPIs among 55 of the 79
reported and predicted P body components were visualized using Cytoscape version 2.6.3. Cyan nodes:
nonsense-mediated decay factors; blue nodes: miRNA-mediated gene silencing factors; pink nodes:
ARE-mediated decay factors; red nodes: decapping factors; yellow nodes: deadenylation factors. Lines
between the nodes represent protein-protein interactions retrieved from STRING or recent publications
in Pubmed.
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4.2.4. Protein-protein interactions between P body proteins and other cellular proteins

Currently little is known about how P body assembly and disassembly is elicited and regulated and
what may be the participating protein factors. Since proteins often alter their functions and subcellular
localization through interactions with other proteins, we reasoned that proteins involved in controlling P
body dynamics and/or themselves also localizing to P bodies may do so via their interactions with P
body component(s). PPIs between human P body proteins and other cellular proteins detected by
affinity purification and yeast two hybrid experiments were retrieved from PINA which integrates PPI
data from six databases (228). Retrieved PPIs were processed with a PHP script and Excel to remove
duplicated records, records with obsolete Uniprot accession numbers, and other unnecessary
information. The processed file was imported to Cytoscape version 2.6.3, where interactants of P body
proteins were grouped and colored differently based on the numbers of interactions between them and P
body factors (Fig. 4.2). P body components were represented with pink nodes in the big circle close to
the bottom, while the nodes in the other differently colored circles represent cellular proteins that
interact with either one (sky blue ; 410 interactions), two (blue; 85 interactions), three (purple; 32
interactions), four (magenta; 10 interactions), five (red; 5 interactions), six (brown; 2 interactions),
seven (yellow; 1 interaction), or eight (green; 2 interactions) P body components (Fig 4.2).
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Figure 4.2: Interactions between P body components and other cellular proteins visualized with
Cytoscape version 2.6.3. P body components were represented with pink nodes in the big circle close
to the bottom, while the nodes in the other differently colored circles represent cellular proteins that
interact with either one, two, three, four, five, six, seven, or eight P body components. Lines between
the nodes represent protein-protein interactions based on either affinity purification and/or yeast twohybrid experiments.
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I reasoned that proteins that can interact with more P body components are more likely to affect P
body dynamics and functions or localize to P bodies. Therefore, I listed the proteins that can interact
with three or more P body components in Table 4.3. Their Uniprot Accession number, number of P
body interactants, and their corresponding P body interactants were also included.

Protein
PABPC1
USP4
LSM8
EXOSC6
SART3
CNOT8
EXOSC10
EXOSC8
SMN1
SNRPE
CNOT6L
CNOT10
DICER1
EEF1A1
HNRNPA1
HSP90AA1
PRPF4
RQCD1
SNRPD2
TOB1
YWHAG
ARRB1
ATG12
BCL6
DDX20
DNAJA1
DOM3Z
EIF4B
EXOSC2
EXOSC4
FLNA
HNRNPK
HSP90AB1
ILF3
INTS6
KPNB1
MATR3
p53
PARN
PRMT5
PUF60
RBM10

UniprotAC
P11940
Q13107
O95777
Q5RKV6
Q15020
Q9UFF9
Q01780
Q96B26
Q16637
P62304
Q96LI5
Q9H9A5
A7E2D3
P68104
P09651
P07900
O43172
Q92600
P62316
P50616
P61981
P49407
O94817
P41182
Q9UHI6
P31689
O77932
P23588
Q13868
Q9NPD3
P21333
P61978
P08238
Q12906
Q9UL03
Q14974
P43243
P04637
O95453
O14744
Q9UHX1
P98175

# of
Interactants
8
8
7
6
6
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3

Interactants
CNOT7,EIF2C1,EIF2C2,EIF2C4,PAN2,PAN3,PCBP1,PCBP2,UPF1
DCP1A,DCP1B,EDC3,LSM2,LSM4,LSM6,LSM7,TRIM21
DCP1A,LSM2,LSM3,LSM4,LSM6,LSM7,UPF1
DCP1B,LSM1,LSM7,UPF2,XRN1,ZFP36
EIF2C1,EIF2C2,LSM2,LSM4,LSM6,LSM7
CNOT1,CNOT2,CNOT3,CNOT6,CNOT7
LSM2,UPF1,UPF2,UPF3A,XRN1
LSM1,LSM7,UPF2,XRN1,ZFP36
GEMIN5,LSM2,LSM4,LSM6,LSM7
GEMIN5,LSM2,LSM3,LSM4,LSM5
CNOT1,CNOT2,CNOT3,NANOS2
CNOT1,CNOT2,CNOT6,CNOT7
EIF2C1,EIF2C2,EIF2C3,EIF2C4
EIF2C2, EIF2C3, EIF2C4, LSM3
EIF2C1, EIF2C2, EIF4E, XRN1
EIF2C3, EIF2C4, LSM1, EIF2AK2
LSM2, LSM4, LSM6, LSM7
CNOT1, CNOT2, CNOT6,CNOT7
LSM2, LSM6, EIF2C4, GEMIN5
CNOT1,CNOT2,CNOT3,CNOT7
LARP1,TRIM21,EDC3,KLC3
HNRNPA3,TUBA1C,YBX1
DDX6,HNRNPA3,MOV10
DDX6,EIF4ENIF1,LSM1
EIF2C2,GEMIN5,LSM2
EIF2C3,EIF2C4,LSM2
DCP2,UPF1,XRN1
EIF2C2,EIF2C3,EIF2C4
UPF1,UPF2,UPF3A
UPF1,UPF2,UPF3A
EIF2C3,PCBP2,PRKACB
PCBP1,PCBP2,YBX1
EIF2C2,EIF2C3,EIF2C4
EIF2C1,EIF2C2,EIF2AK2
EIF4E,UPF1,UPF2
EIF4E,EIF4ENIF1,IPO8
EIF2C1,EIF2C2,PCBP1
EIF2AK2,HTT,YBX1
UPF1,UPF2,UPF3A
EIF2C2,EIF2C3,EIF2C4
HNRNPA3,MOV10,PCBP1
EIF2C2,EIF2C3,EIF2C4
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SF3A2
SLC25A3
SMG1
SNRPD3
USP15
WDR77
YWHAB
YWHAH
YWHAQ
YWHAZ

Q15428
Q00325
Q96Q15
P62318
Q9Y4E8
Q9BQA1
P31946
Q04917
P27348
P63104

3
3
3
3
3
3
3
3
3
3

HNRNPA3,PCBP1,YBX1
EIF2C2,EIF2C3,EIF2C4
UPF1,UPF2,UPF3A
LSM3,LSM7,GEMIN5
LSM2,LSM4,LSM6
EIF2C2,EIF2C3,EIF2C4
EDC3,LARP1,ZFP36
KLC3,LARP1,ZFP36
DDX6,EDC3,LARP1
EDC3,LARP1,TRIM21

Table 4.3: A list of cellular proteins that are reported to interact with three or more P body
components. Proteins in bold have already been reported to be important for P body functions or
formation.

Some of the proteins listed in Table 4.3 (e.g. CNOT6L, CNOT8, and TOB1) are paralogs of
reported P body proteins; therefore it is not surprising that they are identified. Some are more likely to
be involved in functions not directly related to P bodies, such as the 3’ to 5’ riboexonuclease subunits
(EXOSC2, 4, 6, 8, and 10) and the Sm-like protein Lsm8 involved in splicing (124). Interestingly, a few
of the proteins in Table 4.3 have already been reported to be important for P body formation or
functions (see discussion below), such as Hsp90 and 14-3-3 families of proteins (in bold) (206, 224, 229,
230). Therefore, these reports lend support to the feasibility of using this in silico approach to
unraveling potential functions of P bodies and the regulation of P body dynamics. It is very likely that
the rest of the proteins in Table 4.3 are functionally related to P bodies.

4.3. Discussion

A comprehensive list of reported P body proteins in different species has been generated during this
study (Table 4.1). Together, 114 proteins in different species have been reported to localize to P bodies.
Among these P body proteins, 57 are from human, 10 from mouse, 30 from yeast, and 17 from
Arabidopsis, C. elegans, or Drosophila. It should be noted that some of these proteins (e.g. C. elegans
AIN-1, Drosophila GAWKY, Human TNRC6A, TNRC6B, and TNRC6C) are orthologs or paralogs.
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Since orthologs often have similar functions, 22 human proteins whose orthologs have been reported
to localize to P bodies in other species are also predicted to be human P body components (Table 4.2).
The 79 reported and predicted human P body protein components are clustered based on their functions
(Table 4.2). This analysis has yielded some interesting conclusions and/or implications. First, P bodies
contain proteins involved in many aspects of mRNA metabolism, including transcription, splicing,
mRNA transport, mRNA stabilization, mRNA translational inhibition or activation, ARE or nonsensemediated mRNA decay, miRNA-mediated gene silencing, mRNA deadenylaiton, decapping, 5’ to 3’
decay, and endocleavage. Second, although many P body components are mRNA degradation factors,
some P body components are mRNA stabilizers (e.g. eIF4E, HuD, PCBP1, and PCBP2), suggesting that
some of the mRNAs in P bodies may be protected from degradation, which is consistent with the notion
that P bodies can be temporary mRNA storage sites. Third, besides the 5’ to 3’ riboexonuclease Xrn1,
several endonucleases can also be enriched in P bodies; therefore it is possible that decay of some
mRNAs in P bodies might involve endonucleolytic cleavage. It will be interesting to see how knocking
down these endonucleases or their activities may impact P body dynamics. Finally, colocalization of
protein modification factors, including protein kinases and E3 ubiquitin ligases, with P bodies suggests
that phosphorylation and ubiquitination may occur in P bodies to directly modulate P body dynamics or
functions. Conversely, these post-translational modifications may indirectly lead to changes in the
amount or accessibility of P-body proteins for P-body formation.
In this study, I also generate an interactome of P body component. An analysis of protein-protein
interactions (PPIs) among human P body protein components shows that at least two thirds of the
human P body proteins form dense PPI networks (Fig. 4.1), suggesting that collective PPIs among P
body components contribute to the aggregation of mRNPs during P body formation. Moreover, the
result indicates that factors involved in the ARE-mediated decay (pink), miRNA-mediated gene
silencing (blue), and nonsense-mediated decay (cyan) are physically linked. Indeed, the human
nonsense-mediated decay factor Upf1 also participates in small RNA-mediated gene knockdown (175).
Similarly, TTP in the ARE-mediated decay pathway binds to Ago2 and Ago4 in the miRNA-mediated
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gene silencing pathway and is required for mRNA targeting by miR16 (231). Interestingly, although all
of the above three mRNA decay pathways promote deadenylation, only physical interactions between
deadenylation factors (yellow) and miRNA-mediated mRNA decay factors (blue) proteins have been
reported thus far (174). In light of the demonstration that deadenylation is a pre-requisite for P body
formation and that PABP, not found in P body, is involved in the first phase of deadenylation and is
removed from mRNA following deadenylation, the PPI analysis provides new insight into the
mechanism of P body formation. The following sequential events for P body formation may be
envisaged. Following poly(A) shortening via these decay pathways, deadenylases and other
deadenylation associated factors remain on the mRNPs. Deadenylation then elicits mRNP remodeling
that allows other non-deadenylation factors to join the mRNPs. Remodeled mRNPs aggregate into P
bodies via multiple PPIs identified among P body components, including the Pan3 deadenylation factor.
An analysis of protein-protein interactions (PPIs) between human P body protein components and
other cellular proteins identified many factors that interact with three or more P body components (Fig
4.2 and Table 4.3). This in silico approach apparently represents a valid way of identifying factors
potentially involved in regulating P body dynamics. For instance, some proteins belong to non-P body
protein families reported to be required for proper P-body formation and/or function (e.g., Hsp90 and
14-3-3 families) were also included in Table 4.3. Our analysis identified two major cytosolic HSP90
proteins, HSP90AA1 and HSP90AB1, and inhibition of Hsp90 chaperon activity was reported to affect
miRNA-mediated gene silencing, siRNA-directed cleavage of target mRNA, and P body formation (229,
230). We also identified the 14-3-3 protein family (YWHAG, YWHAB, YWHAH, YWHAQ, and
YWHAZ), which bind to phosphoserine-containing proteins. It is reported that binding of 14-3-3 to
Edc3 alters P body morphology, inhibits miRNA-mediated gene silencing, and changes Edc3 proteinprotein interactions (206). In addition, the sorting of hMex-3B between P bodies and stress granules is
regulated by the interaction between hMex-3B and 14-3-3 proteins (224), although this interaction was
not retrieved using PINA and therefore not included during the analysis. The interactions between 14-33 family proteins and several other reported or predicted P body components (Table 4.3), including
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LARP1, KLC3, TRIM21 (Ro52), TTP (ZFP36), RCK/p54 (DDX6), suggest that 14-3-3 family of
proteins play more important roles in regulating P body functions than they were previously thought. It
is also worth noting that the identification of the interactions between Ago proteins and PABP, which is
not enriched in mammalian P bodies (21, 71), is consistent with the recent finding that PABP was
required for miRNA-mediated deadenylation (174).
Therefore, PPIs support a hypothesis that the other proteins listed in Table 4.3 may also have P
body-related functions or even colocalize with P bodies. It will be interesting to test whether or not
knockdown of these proteins will affect P-body dynamics and whether these proteins themselves
localize to P bodies as well.
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Chapter 5: Perspectives and Prospects

Page | 90

mRNA poly(A) tails, which are essential for both mRNA stability and translation, can be shortened
in a process termed deadenylation by deadenylases. In this study, I found that the two major mammalian
deadenylase complexes, Pan3-Pan2 and Ccr4-Caf1, can both localize to mammalian mRNA processing
bodies (P bodies), which are normally thought to be cytoplasmic sites for mRNA translational inhibition,
mRNA decapping, and 5’ to 3’ mRNA degradation. More importantly, my experiments demonstrated
that deadenylation by the Ccr4-Caf1 complex is a prerequisite for P body formation in mammalian cells.
One of the consequences of deadenylation is dissociation of ribosomes from mRNAs. It was known
that dissociation of ribosomes from mRNAs to render the mRNAs translationally silent is necessary for
the mRNAs to enter or form P bodies. However, it was not clear whether the dissociation step alone is
sufficient or whether other steps are also required. My work revealed an intriguing finding that even
when ribosomes are forced to be released from cytoplasmic mRNAs by puromycin treatment,
deadenylation is still required for P body formation. Given that deadenylation leads to translation
repression or formation of non-translatable mRNPs, one possible scenario is as follow: when
deadenylation is inhibited, the poly(A) binding proteins (PABPs) associated with the poly(A) tails
inhibit mRNAs from forming P bodies by promoting mRNA circularization and preventing the
displacement of translation activators by specific translation inhibitors that are also found in P bodies. It
will be interesting to test this hypothesis by analyzing protein components of mRNPs from cells whose
translation and deadenylation are blocked.
Unlike the Ccr4-Caf1 complex, the roles of the Pan3-Pan2 complex in P body formation appear to
be more complicated. Unlike overexpressing the Caf1 catalytically inactive mutant, overexpression of a
Pan2 catalytic mutant didn’t inhibit P body formation, suggesting that Pan2 deadenylase activity is not
essential for P body formation. Consistently, siRNA-mediated knockdown of Pan2 has little effect on P
bodies. Interestingly, Pan3 mutants with C-terminal domain truncation, which no longer interact with
Pan2, still formed many cytoplasmic foci co-localizing with P bodies. The N-terminal domain and
kinase domain of Pan3, although not required for interaction with Pan2, are thus both important for
Pan3 to co-localize with P bodies. Moreover, ectopic expression of Pan3 mutants with phosphorylation
sites mutated at the N-terminal domain, e.g., NP11, results in P body morphology change. Collectively,
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these observations argue that Pan3 possesses Pan2-independent functions that are essential for P body
formation.
What could be the Pan2-unrelated functions of Pan3 during P body formation? A clue comes from a
discrepancy between a reported observation and my experimental results. In vitro, purified Pan2 was
reported to shorten oligo(A) in the absence of Pan3 and PABP. However, I observed that tethered Pan3
mutants with deletions in the N-terminal domain or kinase domain failed to induce fast deadenylation of
the reporter mRNA, even though these mutants can still interact with Pan2. One possibility is that in my
in vivo experiment PABPs associated with the poly(A) tail may block the deadenylase activity of Pan2
recruited by Pan3 mutants while in the reported in vitro experiment no PABP is present in the reaction.
The observation that tethered wild-type Pan3, but not Pan3 truncation mutants, induced fast
deadenylation suggests that Pan3 N-terminal and kinase domains may be required to promote
dissociation of PABPs from the poly(A) tail. Therefore Pan3 alone might be able to remove PABP from
the poly(A) tail and allow these poly(A)+ mRNAs to enter P bodies, which might explain why HAtagged Pan3 promotes the enrichment of Ccr4-Caf1 and other P body components, but not PABP, in P
bodies. This hypothesis can be tested by checking the ability of Pan3 or Pan3 mutants (e.g., deficient in
Pan2 binding) to release PABPs from the poly(A) tail of reporter mRNAs using cytoplasmic lysates
prepared from cells expressing Pan2 catalytic mutant.
Another possible Pan2-independent function of Pan3 in P body formation may involve the Pan3Pan3 self-interaction as discovered in yeast (33) and suggested by my preliminary observations in NIH
3T3 cells. The Pan3-Pan3 self-interaction may promote aggregation of mRNPs during P body formation.
To further confirm that Pan3 self-interacts within P bodies, the distance between YFP-Pan3 and CFPPan3 in P bodies can be measured using fluorescence resonance energy transfer (FRET).
Pan3 N-terminal domain may be phosphorylated to regulate Pan3 localization and functions. Guided
by two different methods for phosphorylation site prediction, I focused on eleven potential
phosphorylation sites in Pan3 N-terminal domain. NP11, the Pan3 mutant where the eleven potential
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phosphorylation sites were replaced by alanine or phenylalaline, induced large and irregularly shaped P
body formation. On the other hand, PM11, the Pan3 mutant mimicking phosphorylation at the eleven
sites, no longer colocalizes with P bodies. Instead, it forms nuclear foci. Interestingly, HA-tagged wildtype Pan3 can also form nuclear foci and be hyper-phosphorylated upon Leptomycin B treatment. Like
th wild-type Pan3, these two mutants are able to promote reporter mRNA deadenylation and decay
when tethered to the reporter. It will be interesting to confirm phosphorylation of Pan3 N-terminal
domain and identify the phosphorylated residues by mass spectrometry analysis of affinity purified HAPan3. Once the phosphorylated sites in Pan3 N-terminal domain are identified, the effects of mutations
mimicking or inhibiting phosphorylation at those sites on Pan3 localization and functions can then be
determined.
The observation that Pan3(1-353) and Pan3(PM11) formed nuclear foci suggests that Pan3 may play
a role in the nucleus. In addition, wild-type Pan3 also formed nuclear foci when the cells were treated
with Leptomycin B, an inhibitor of the nuclear export receptor CRM1. In yeast, Pan3p-Pan2p complex
trims the poly(A) tails of newly synthesized mRNAs to message-specific length, although it was not
clear whether this occurs in the nucleus or in the cytoplasm (35). My observations suggest that Pan3Pan2 may also trim the poly(A) tails of nascent mRNAs in the nucleus in mammalian cells. To test this
possibility, we can check if siRNA-mediated knock down of Pan3 or Pan2 results in formation of longer
poly(A) tails of nuclear mRNA. Since Pan3 nuclear localization may correlate with Pan3
hyperphosphorylation, it will also be interesting to determine whether Pan3 phosphorylation affects any
potential nuclear function of Pan3.
Aside from focusing on the functions of the two deadenylation complexes in P bodies, I have also
compiled a list of reported P body protein components and predicted new human P body proteins based
on sequence homology. The reported and predicted human P body components were categorized
according to their functions, and their protein-protein interaction networks were visualized and analyzed.
This effort not only has helped us to better understand the functions of and interactions among human P
body proteins, but also has yielded some interesting predictions. For instance, my study suggests that
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cellular proteins able to interact with three or more P body components may also localize to P bodies or
play a role in P body functions. In agreement with this prediction, some of the identified proteins have
already been reported to be important for P body formation or functions. Future experiments along this
line will be to determine P body-related functions of proteins selected in this study. These experiments
may reveal novel P body components and post-translational modification pathways that control P body
dynamics.
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